落新妇甙对肝脏热缺血再灌注损伤保护作用的分子机制研究
|
摘要
研究背景
肝移植已经成为治疗多数急、慢性终末期肝病的首选方法。但是存在于每一例肝移植过程中的缺血再灌注损伤(IRI)仍然是原发性移植物功能不良或无功能的主要原因。供体的短缺使得移植中心不断扩大使用边缘供体的尺度,包括老龄供体、无心跳供体、小体积供肝及脂肪肝。而边缘供体带来的基本问题仍然是IRI。因此,最大限度的减轻IRI不但可以增加适当的供体,也可以使更多的病人从肝移植手术中康复。而实现这一愿望的首要步骤就是更加充分的理解I/R损伤的机制。
肝脏是对缺血再灌注损伤最敏感的器官之一。肝窦内皮细胞、Kupfer cells和中性粒细胞的活化以及氧自由基的产生在缺血再灌注损伤的病理过程中具有重要作用。氧自由基和炎症细胞因子、粘附分子进一步促进中性粒细胞的活化与聚集,介导脂质过氧化损伤等过程,最终导致肝组织损伤。
1997年发现的Toll样受体系统(TLRs)在感染和炎症性疾病中扮演重要角色。其中的TLR-4信号通路被认为在心脏、肾脏和肝脏的IRI病理生理过程中居主导地位。TLR-4分子存在于所有肝实质、非实质细胞上,每种肝细胞群体都拥有完整的TLR-4信号通路。激活的肝脏非实质细胞(尤其Kupffer细胞)通过TLR-4信号通路在肝脏热缺血再灌注损伤中发挥重要作用。TLR-4的激活引出NF-κB激活,进一步触发TNF-a、IL-1、IL-6等炎症因子的大量产生。因为TLR-4信号通道在肝脏缺血再灌注损伤中的重要作用,通过抑制该信号通路达到减轻肝脏IRI的目的就显得前景诱人。HO-1是热休克蛋白32成员,肝脏HO-1最初由Kupffer细胞产生,作为TLR-4的配体之一,通过阻抑TLR-4信号通路产生较强的抗氧化、抗炎症功能从而起到保护肝脏IRI的作用。
另一方面,细胞因子信号转导抑制分子1(Supressors of cytokine signalingl,SOCS1)是一种负性调节因子。能通过负性调控JAK-STAT信号途径而抑制ILs、IFN-γ、GH等多种细胞因子的信号转导途径。SOCS1还参与其它信号途径的调节,如TNF-a、LPS等。SOCS1的过表达在体外能明显减轻TNF-a引起的肝细胞凋亡,而TNF-a被认为是TLR-4活化的标志。提示SOCS1可能是负调节TLR-4及其信号转导系统的内源性因子之一。研究显示IL-10能够促进SOCS蛋白的产生,尤其是SOCS1和SOCS3。研究者在包括肝脏的许多缺血再灌注损伤模型中都能观察到IL-10的抑制炎症、保护组织的作用。因此如有药物能促进体内IL-10表达,则可能通过SOCS1负调节信号通道在肝脏IRI中发挥保护作用。
落新妇甙(Astilbin)是从土茯苓的乙醇提取液中分离得到的3个二氢黄酮醇甙之一。黄酮类化合物有较强的抗氧化作用,可作为递氢体清除氧自由基,从而在抗炎、减轻缺血再灌注损伤等方面发挥作用。研究证实其具有利尿、镇痛、抗炎及减轻心肌细胞缺血再灌注损伤的作用。有研究报道落新妇甙能够通过干预氧自由基和脂质过氧化物生成,明显减轻四氯化碳(CC14)引起的肝损伤;在刀豆球蛋白A(Con A)诱导肝炎后,落新妇甙能够显著降低TNF-a的生成和肝脏Kupffer细胞的增殖,并且落新妇甙在接触性皮炎模型中能显著促进IL-10和SOCS1和SOCS3的表达,减轻炎症反应。
基于上述研究背景,本课题进一步研究:1)落新妇甙对肝脏热缺血再灌注损伤的保护效果,包括肝功能、肝脏病理、SOD、MDA、MPO的检测;2)落新妇甙对肝脏缺血再灌注损伤模型中TLR-4、HO-1、NF-κB、TNF-a等分子蛋白和mRNA水平表达的影响,探讨其抑制炎症信号通路的分子机制;3)落新妇甙对IL-10、SOCS1蛋白和mRNA表达的影响,探讨其促进抑炎信号通路的分子机制。通过上述研究,为以后在同种异体小鼠肝移植模型中研究落新妇甙对缺血再灌注损伤保护,免疫抑制效果及机制进行基础准备。
第一部分落新妇甙对肝脏热缺血再灌注损伤的干预作用
目的:探讨落新妇甙在肝脏热缺血再灌注损伤中对肝功能和肝组织的保护效果。
方法:C57BL/6小鼠随机分为4组(n=8):假手术组(Sham)、模型组(I/R)、落新妇甙小剂量(10mg/kg)干预组和落新妇甙大剂量(40mg/kg)干预组。缺血前24小时和1小时干预组小鼠腹腔注射分别给予10或40mg/kg的落新妇甙,建立肝左、中叶70%部分肝缺血再灌注模型,模型组和假手术组给予同样体积的生理盐水。小鼠肝脏左叶缺血90min、再灌注6h后各实验组采集血液和肝脏组织样本。检测血清中ALT活性作为肝功能损伤的指标,同时用ELISA检测肝组织中MPO、SOD和MDA含量。肝脏组织病理学检测。结果:与模型对照组相比,小、大剂量落新妇甙干预组血清ALT含量均明显下降(P＜0.01),大剂量干预组较小剂量组更明显(P＜0.01);落新妇甙大剂量干预后肝脏组织病理学表现明显改善;落新妇甙干预后肝组织MPO、MDA含量较模型对照组明显下降(P＜0.01),大剂量干预组较小剂量组更明显(P＜0.01);而SOD含量明显上升(P＜0.01),大剂量干预组较小剂量组明显(P＜0.05)。结论:落新妇甙干预能有效改善小鼠肝脏热缺血再灌注损伤引起的肝功能和肝脏病理损害;落新妇甙干预能够减轻小鼠肝脏热缺血再灌注损伤后中性粒细胞的聚集浸润和活化,从而减轻炎症反应;落新妇甙能减少缺血再灌注后氧自由基的产生,减轻脂质过氧化引发的组织损伤。
第二部分落新妇甙对肝缺血再灌注损伤TLR-4信号通路的抑制作用
目的:通过观察落新妇甙对肝脏热缺血再灌注损伤中炎症信号通路的影响,探讨其缺血再灌注保护作用的分子机制。方法:C57BL/6小鼠随机分为4组(n=5):假手术组(Sham)、模型组(I/R)、落新妇甙小剂量(10mg/kg)干预组和落新妇甙大剂量(40mg/kg)干预组。缺血前24小时和1小时干预组小鼠腹腔注射分别给予10或40mg/kg的落新妇甙,建立肝左、中叶70%部分肝缺血再灌注模型,模型组和假手术组给予同样体积的生理盐水。小鼠肝脏左叶缺血90min、再灌注6h后各实验组采集血液和肝脏组织样本。检测血清中TNF-a活性,Westernblot检测肝组织中TNF-a、TLR-4、NF-κB和HO-1蛋白含量,半定量RT-PCR检测上述分子mRNA表达情况。结果:落新妇甙小、大剂量干预后血清TNF-a含量较I/R对照组均明显下降(P＜0.01),且呈现剂量—效益关系(P＜0.01);落新妇甙小、大剂量干预组肝组织中TNF-a、TLR-4、NF-κB蛋白表达与I/R模型对照组比较均渐次降低,与半定量RT-PCR结果相符(小剂量干预组P＜0.05;大剂量干预组P＜0.01);而落新妇甙小、大剂量干预组肝组织中HO-1蛋白表达与I/R模型对照组比较均渐次升高,亦与半定量RT-PCR结果相符(小剂量干预组P＜0.05;大剂量干预组P＜0.01)。结论:落新妇甙干预能降低缺血再灌注损伤引起的血清TNF-a水平升高以及TNF-a蛋白及mRNA在肝组织中的高表达,从而减轻由TNF-a介导的进一步损伤;落新妇甙干预能降低IRI肝组织中TLR-4蛋白、mRNA和NF-κB蛋白的高表达,显示其对TLR-4炎症信号通路具有抑制作用。落新妇甙干预能促进IRI肝组织HO-1蛋白和mRNA的表达,显示其对TLR-4通路的抑制与促进HO-1的表达密切相关。
第三部分落新妇甙对肝缺血再灌注损伤SOCS1、IL-10表达的影响
目的:通过观察落新妇甙对肝脏热缺血再灌注损伤中抑炎症信号通路的影响,进一步探讨其缺血再灌注保护作用的分子机制。方法:C57BL/6小鼠随机分为4组:假手术组(Sham)、模型组(I/R)、落新妇甙小剂量(10mg/kg)干预组和落新妇甙大剂量(40mg/kg)干预组。缺血前24小时和1小时干预组小鼠腹腔注射分别给予10或40mg/kg的落新妇甙,建立肝左、中叶70%部分肝缺血再灌注模型,模型组和假手术组给予同样体积的生理盐水。小鼠肝脏左叶缺血90min、再灌注6h后各实验组采集血液和肝脏组织样本。Westernblot检测肝组织中SOCS-1、IL-10蛋白含量,半定量RT-PCR检测上述分子mRNA表达情况。结果:落新妇甙小、大剂量干预组肝组织中SOCS-1、IL-10蛋白表达与I/R模型对照组比较均渐次升高,与半定量RT-PCR结果相符(小剂量干预组P＜0.05;大剂量干预组P＜0.01)。结论:落新妇甙干预能促进缺血再灌注损伤肝组织中IL-10蛋白及mRNA在的高表达,从而起到抑制炎症的作用;落新妇甙干预能促进缺血再灌注损伤肝组织SOCS1蛋白和mRNA的表达,显示其可能通过上调SOCS1负调节通路产生抑制炎症的作用。
Experimental Study on the molecular mechanism of the effect of astilbin on liver warm ischemia-reperfusion injury
Liver transplantation has become the method of choice for treatment of the majority of acute and chronic end-stage liver disease.However,ischemia-reperfusion injury(IRI) existing in every case of liver transplantation is still the main reason of primary graft dysfunction or non-function.The shortage of donor leads to the growing use of the marginal donor in most transplant centres,including the aging donor,non-heart-beating donors,small size and fatty liver donor,while the basic problem of the marginal donor is still IRI.So,reducing IRI maximatily would not only increase the appropriate donors,but also allow more patients recovery from liver transplant surgery.And to achieve this desire, firstly,we should understand the mechanisms of I/R injury more fully.
Liver is one of the most sensitive organs to ischemia-reperfusion injury.The activation of sinusoidal endothelial cells,Kupfer cells and neutrophil and the formation of oxygen free radicals plays an important role in the pathological process of ischemia-reperfusion injury.Oxygen free radicals and inflammatory cytokines,adhesion molecules further promote neutrophil activation and aggregation,mediate lipid peroxidation injury process, which eventually lead to liver damage.
The Toll-like receptors(TLRs) found in 1997 play an important role in the disease of infection and inflammation.The TLR-4 signaling pathway was considered to be dominated in the pathophysiological process of heart,kidney and liver IRI.TLR-4 molecule exists in all of hepatic parenchyma,non-parenchymal cells,each group of liver cells has a complete TLR-4 signaling pathway.Activated hepatic non-parenchymal cells(especially Kupffer cells) play an important role in the liver warm ischemia-reperfusion injury through TLR-4 signaling pathway.Activated TLR-4 leads to the activation of NF-κB,which further triggers great increase of inflammatory cytokines such as TNF-a,IL-1,IL-6,et al.Because of the important role of TLR-4 signaling pathway in liver ischemia-reperfusion injury,the purpose of reducing liver IRI by inhibiting this signaling pathway is of enticing prospects. HO-1 is a heat shock protein 32 members.Liver HO-1 was first produced by Kupffer cells. As one of the TLR-4 ligands,it has strong antioxidant,anti-inflammatory function thus protecting liver IRI by inhibiting TLR-4 signaling pathway.
On the other hand,SOCS1 is a negative regulator molecule,which inhibit ILs,IFN-γ, GH,and other cytokine signal transduction pathway through negative regulation of JAK-STAT signaling pathway.SOCS1 also involves in the regulation of other signaling pathways,such as TNF-a,LPS.The over-expression of SOCS1 in vitro can significantly reduce the hepatocytes apoptosis induced by TNF-a,while TNF-a is considered TLR-4 activation marker,implying that SOCS1 may be one of the endogenous negative regulators of TLR-4 signal transduction systems.Studies show that IL-10 can promote the formation of SOCS protein,in particular the SOCS1 and SOCS3.The role of inhibiting inflammation and protecting organizations of IL-10 can be observed in many models of ischemia -reperfusion injury,including liver.So if drugs can promote IL-10 expression in vivo,it could play a protective role in the liver IRI through regulating SOCS1 negative signal pathway.
Astilbin is one of the three flavanonols isolated from the ethanol extract of rhizoma. Flavonoids have strong function of antioxidant and can be used as delivery of hydrogen to scavenging oxygen free radicals,resulting in anti-inflammatory and reducing ischemia-reperfusion injury.Researches have confirmed its role of diuretic,analgesic, anti-inflammatory and reduce myocardial ischemia-reperfusion injury.As reported that astilbin could significantly reduce the liver damage induced by carbon tetrachloride(CC14) through the intervention of oxygen free radicals and lipid peroxide formation;In concanavalin A(Con A)-induced hepatitis,astilbin could significantly reduce TNF-a production and the proliferation of liver Kupffer cells.And in a contact dermatitis model, astilbin could significantly promote the expression of IL-10 and SOCS1 and SOCS3, reducing inflammatory response.
Based on these research backgrounds,further study will be involved in this topic: 1)The protective effects of astilbin on liver warm ischemia-reperfusion injury,including liver function,liver pathology,SOD,MDA,the MPO detection;2) The effects of astilbin on the expression of TLR-4,HO-1,NF-κB,TNF-a protein and mRNA in the liver ischemia-reperfusion injury model,to investigate the molecular mechanisms of inhibiting inflammation signal pathway;3) The effects of astilbin on the expression of IL-10,SOCS1 protein and mRNA,to explore the molecular mechanism of promoting anti-inflammation signaling pathway.Based on these researches,to prepare for the further study on the mechanisms of protective and immunosuppressive effects of astilbin on liver ischemia and reperfusion injury,in the liver transplantation model of allogeneic mice.
PARTⅠ.Effect of astilbin on liver warm ischemia-reperfusion injury
Objective:To investigate the protective effect of astilbin on liver function and hepatic tissues in the liver warm ischemia-reperfusion injury.Methods:C57BL/6 mice were randomly divided into four groups(n=8):sham-operated group(Sham),model control group(I/R),low dosage of astilbin treatment group(10mg/kg) and large dosage of astilbin(40mg/kg) treatment group.24 hours and one hour before Ischemia,treatment group mice were intraperitoneally injected 10 or 40 mg/kg astilbin.Then the hepatic ischemia-reperfusion model of 70 percent of liver,including the left and middle hepatic lobe,were established.The I/R model control group and the sham operation group were administered with the same volume of normal saline.After 90 min ischemia and 6h reperfusion of the partial hepatic lobe,blood and liver tissue samples were collected from the experimental groups.Serum ALT activity was detected as an indicator of liver function damage,and the content of MDA,MPO,SOD in liver tissues were detected by ELISA. Histopathology detection was performed.Results:Compared with the I/R model control group,serum ALT in both treatment group of the low and large dosage astilbin were significantly decreased(P＜0.01),even lower in the large dosage group than in the low dosage group(P＜0.01).Hepatic pathology performance improved significantly in the large dosage group;The content of MDA,MPO in liver tissues were significantly decreased in both treatment groups when compared with the I/R model control group(P＜0.01),also lower in the large dosage group than in the low dosage group(P＜0.01).And SOD levels significantly increased in treatment groups(P＜0.01),higher in the large dosage group than in the low dosage group(P＜0.05).Couclusiou:Treatment with astilbin can effectively improve the mouse liver function and liver pathology damage induced by liver warm ischemia-reperfusion injury;Intervention with astilbin can reduce the aggregation, infiltration and activation of neutrophil in the mouse liver induced by warm ischemia-reperfusion injury,thereby reducing inflammatory response;Intervention with astilbin can inhibit the formation of oxygen free radicals,and reduce the damage of lipid peroxidation induced by liver ischemia-reperfusion injury.
PARTⅡ.Inhibiting Effect of Astilbin on TLR-4 Signaling Pathway in Liver warm ischemia-reperfusion injury
Objective:To study the molecular mechanism of the effect of astilbin on inhibiting the inflammation signaling pathway in liver warm ischemia-reperfusion injury.Methods: C57BL/6 mice were randomly divided into four groups(n=5):sham-operated group (Sham),model control group(I/R),low dosage of astilbin treatment group(10mg/kg) and large dosage of astilbin(40mg/kg) treatment group.24 hours and one hour before Ischemia, treatment group mice were intraperitoneally injected 10 or 40 mg/kg astilbin.Then the hepatic ischemia-reperfusion model of 70 percent of liver,including the left and middle hepatic lobe,were established.The I/R model control group and the sham operation group were administered with the same volume of normal saline.After 90 min ischemia and 6h reperfusion of the partial hepatic lobe,blood and liver tissue samples were collected from the experimental groups.Serum TNF-a activity was detected,and the content of TNF-a、TLR-4、NF-κB and HO-1 in liver tissues were detected by western blot.mRNA expression of these proteins was detected by semiquantitative RT-PCR.Results:Compared with the I/R model control group,serum TNF-a in both treatment group of the low and large dosage astilbin were significantly decreased(P＜0.01),even lower in the large dosage group than in the low dosage group(P＜0.01).The protein content of TNF-a、TLR-4、NF-κB in liver tissues were gradually decreased in both treatment groups when compared with the I/R model control group,also lower in the large dosage group than in the low dosage group. Same trends were observed in the mRNA expression of these proteins showed by semiquantitative RT-PCR(low dosage group P＜0.05;large dosage group P＜0.01).HO-1 levels gradually increased in treatment groups,higher in the large dosage group than in the low dosage group,the result of mRNA showed a same trend(low dosage group P＜0.05; large dosage group P＜0.01).Conclusion:Intervention with astilbin can reduce the high levels of serum TNF-a caused by ischemia-reperfusion injury,as well as increased expression of TNF-a protein and mRNA in the liver tissues,thereby reducing TNF-a-mediated further injury;Intervention with astilbin can reduce the high expression of TLR-4 protein and mRNA,and NF-κB protein in IRI liver tissues,demonstrating its effect of inhibiting TLR-4 inflammation signaling pathway.Treatment with astilbin can promote the expression of HO-1 protein and mRNA in IRI liver,demonstrating its effect of TLR-4 pathway inhibition and promotion of the expression of HO-1 is closely related.
PARTⅢ.Effect of Astilbin on Expression of SOCS1、IL-10 in Liver warm ischemia-reperfusion injury
Objective:To study the molecular mechanism of the effect of astilbin on the anti-inflammation signaling pathway in liver warm ischemia-repeffusion injury.Methods: C57BL/6 mice were randomly divided into four groups(n=5):sham-operated group (Sham),model control group(I/R),low dosage of astilbin treatment group(10mg/kg) and large dosage of astilbin(40mg/kg) treatment group.24 hours and one hour before Ischemia, treatment group mice were intraperitoneally injected 10 or 40 mg/kg astilbin.Then the hepatic ischemia-reperfusion model of 70 percent of liver,including the left and middle hepatic lobe,were established.The I/R model control group and the sham operation group were administered with the same volume of normal saline.After 90 min ischemia and 6h reperfusion of the partial hepatic lobe,liver tissue samples were collected from the experimental groups.The content of SOCS-1 and IL-10 in liver tissues were detected by western blot.mRNA expression of the same proteins was detected by semiquantitative RT-PCR.Results:Compared with the I/R model control group,SOCS-1 and IL-10 protein levels gradually increased in treatment groups,higher in the large dosage group than in the low dosage group,the result of mRNA showed a same trend(low dosage group P＜0.05; large dosage group P＜0.01).Conclusion:Intervention with astilbin can promote the expression of IL-10 protein and mRNA in IRI liver,thus inhibiting the inflammation; Intervention with astilbin can promote the expression of SOCS-1 protein and mRNA in IRI liver,showing its role of negative regulation by upregulating SOCS1 pathway.
肝移植已经成为治疗多数急、慢性终末期肝病的首选方法。但是存在于每一例肝移植过程中的缺血再灌注损伤(IRI)仍然是原发性移植物功能不良或无功能的主要原因。供体的短缺使得移植中心不断扩大使用边缘供体的尺度,包括老龄供体、无心跳供体、小体积供肝及脂肪肝。而边缘供体带来的基本问题仍然是IRI。因此,最大限度的减轻IRI不但可以增加适当的供体,也可以使更多的病人从肝移植手术中康复。而实现这一愿望的首要步骤就是更加充分的理解I/R损伤的机制。
肝脏是对缺血再灌注损伤最敏感的器官之一。肝窦内皮细胞、Kupfer cells和中性粒细胞的活化以及氧自由基的产生在缺血再灌注损伤的病理过程中具有重要作用。氧自由基和炎症细胞因子、粘附分子进一步促进中性粒细胞的活化与聚集,介导脂质过氧化损伤等过程,最终导致肝组织损伤。
1997年发现的Toll样受体系统(TLRs)在感染和炎症性疾病中扮演重要角色。其中的TLR-4信号通路被认为在心脏、肾脏和肝脏的IRI病理生理过程中居主导地位。TLR-4分子存在于所有肝实质、非实质细胞上,每种肝细胞群体都拥有完整的TLR-4信号通路。激活的肝脏非实质细胞(尤其Kupffer细胞)通过TLR-4信号通路在肝脏热缺血再灌注损伤中发挥重要作用。TLR-4的激活引出NF-κB激活,进一步触发TNF-a、IL-1、IL-6等炎症因子的大量产生。因为TLR-4信号通道在肝脏缺血再灌注损伤中的重要作用,通过抑制该信号通路达到减轻肝脏IRI的目的就显得前景诱人。HO-1是热休克蛋白32成员,肝脏HO-1最初由Kupffer细胞产生,作为TLR-4的配体之一,通过阻抑TLR-4信号通路产生较强的抗氧化、抗炎症功能从而起到保护肝脏IRI的作用。
另一方面,细胞因子信号转导抑制分子1(Supressors of cytokine signalingl,SOCS1)是一种负性调节因子。能通过负性调控JAK-STAT信号途径而抑制ILs、IFN-γ、GH等多种细胞因子的信号转导途径。SOCS1还参与其它信号途径的调节,如TNF-a、LPS等。SOCS1的过表达在体外能明显减轻TNF-a引起的肝细胞凋亡,而TNF-a被认为是TLR-4活化的标志。提示SOCS1可能是负调节TLR-4及其信号转导系统的内源性因子之一。研究显示IL-10能够促进SOCS蛋白的产生,尤其是SOCS1和SOCS3。研究者在包括肝脏的许多缺血再灌注损伤模型中都能观察到IL-10的抑制炎症、保护组织的作用。因此如有药物能促进体内IL-10表达,则可能通过SOCS1负调节信号通道在肝脏IRI中发挥保护作用。
落新妇甙(Astilbin)是从土茯苓的乙醇提取液中分离得到的3个二氢黄酮醇甙之一。黄酮类化合物有较强的抗氧化作用,可作为递氢体清除氧自由基,从而在抗炎、减轻缺血再灌注损伤等方面发挥作用。研究证实其具有利尿、镇痛、抗炎及减轻心肌细胞缺血再灌注损伤的作用。有研究报道落新妇甙能够通过干预氧自由基和脂质过氧化物生成,明显减轻四氯化碳(CC14)引起的肝损伤;在刀豆球蛋白A(Con A)诱导肝炎后,落新妇甙能够显著降低TNF-a的生成和肝脏Kupffer细胞的增殖,并且落新妇甙在接触性皮炎模型中能显著促进IL-10和SOCS1和SOCS3的表达,减轻炎症反应。
基于上述研究背景,本课题进一步研究:1)落新妇甙对肝脏热缺血再灌注损伤的保护效果,包括肝功能、肝脏病理、SOD、MDA、MPO的检测;2)落新妇甙对肝脏缺血再灌注损伤模型中TLR-4、HO-1、NF-κB、TNF-a等分子蛋白和mRNA水平表达的影响,探讨其抑制炎症信号通路的分子机制;3)落新妇甙对IL-10、SOCS1蛋白和mRNA表达的影响,探讨其促进抑炎信号通路的分子机制。通过上述研究,为以后在同种异体小鼠肝移植模型中研究落新妇甙对缺血再灌注损伤保护,免疫抑制效果及机制进行基础准备。
第一部分落新妇甙对肝脏热缺血再灌注损伤的干预作用
目的:探讨落新妇甙在肝脏热缺血再灌注损伤中对肝功能和肝组织的保护效果。
方法:C57BL/6小鼠随机分为4组(n=8):假手术组(Sham)、模型组(I/R)、落新妇甙小剂量(10mg/kg)干预组和落新妇甙大剂量(40mg/kg)干预组。缺血前24小时和1小时干预组小鼠腹腔注射分别给予10或40mg/kg的落新妇甙,建立肝左、中叶70%部分肝缺血再灌注模型,模型组和假手术组给予同样体积的生理盐水。小鼠肝脏左叶缺血90min、再灌注6h后各实验组采集血液和肝脏组织样本。检测血清中ALT活性作为肝功能损伤的指标,同时用ELISA检测肝组织中MPO、SOD和MDA含量。肝脏组织病理学检测。结果:与模型对照组相比,小、大剂量落新妇甙干预组血清ALT含量均明显下降(P＜0.01),大剂量干预组较小剂量组更明显(P＜0.01);落新妇甙大剂量干预后肝脏组织病理学表现明显改善;落新妇甙干预后肝组织MPO、MDA含量较模型对照组明显下降(P＜0.01),大剂量干预组较小剂量组更明显(P＜0.01);而SOD含量明显上升(P＜0.01),大剂量干预组较小剂量组明显(P＜0.05)。结论:落新妇甙干预能有效改善小鼠肝脏热缺血再灌注损伤引起的肝功能和肝脏病理损害;落新妇甙干预能够减轻小鼠肝脏热缺血再灌注损伤后中性粒细胞的聚集浸润和活化,从而减轻炎症反应;落新妇甙能减少缺血再灌注后氧自由基的产生,减轻脂质过氧化引发的组织损伤。
第二部分落新妇甙对肝缺血再灌注损伤TLR-4信号通路的抑制作用
目的:通过观察落新妇甙对肝脏热缺血再灌注损伤中炎症信号通路的影响,探讨其缺血再灌注保护作用的分子机制。方法:C57BL/6小鼠随机分为4组(n=5):假手术组(Sham)、模型组(I/R)、落新妇甙小剂量(10mg/kg)干预组和落新妇甙大剂量(40mg/kg)干预组。缺血前24小时和1小时干预组小鼠腹腔注射分别给予10或40mg/kg的落新妇甙,建立肝左、中叶70%部分肝缺血再灌注模型,模型组和假手术组给予同样体积的生理盐水。小鼠肝脏左叶缺血90min、再灌注6h后各实验组采集血液和肝脏组织样本。检测血清中TNF-a活性,Westernblot检测肝组织中TNF-a、TLR-4、NF-κB和HO-1蛋白含量,半定量RT-PCR检测上述分子mRNA表达情况。结果:落新妇甙小、大剂量干预后血清TNF-a含量较I/R对照组均明显下降(P＜0.01),且呈现剂量—效益关系(P＜0.01);落新妇甙小、大剂量干预组肝组织中TNF-a、TLR-4、NF-κB蛋白表达与I/R模型对照组比较均渐次降低,与半定量RT-PCR结果相符(小剂量干预组P＜0.05;大剂量干预组P＜0.01);而落新妇甙小、大剂量干预组肝组织中HO-1蛋白表达与I/R模型对照组比较均渐次升高,亦与半定量RT-PCR结果相符(小剂量干预组P＜0.05;大剂量干预组P＜0.01)。结论:落新妇甙干预能降低缺血再灌注损伤引起的血清TNF-a水平升高以及TNF-a蛋白及mRNA在肝组织中的高表达,从而减轻由TNF-a介导的进一步损伤;落新妇甙干预能降低IRI肝组织中TLR-4蛋白、mRNA和NF-κB蛋白的高表达,显示其对TLR-4炎症信号通路具有抑制作用。落新妇甙干预能促进IRI肝组织HO-1蛋白和mRNA的表达,显示其对TLR-4通路的抑制与促进HO-1的表达密切相关。
第三部分落新妇甙对肝缺血再灌注损伤SOCS1、IL-10表达的影响
目的:通过观察落新妇甙对肝脏热缺血再灌注损伤中抑炎症信号通路的影响,进一步探讨其缺血再灌注保护作用的分子机制。方法:C57BL/6小鼠随机分为4组:假手术组(Sham)、模型组(I/R)、落新妇甙小剂量(10mg/kg)干预组和落新妇甙大剂量(40mg/kg)干预组。缺血前24小时和1小时干预组小鼠腹腔注射分别给予10或40mg/kg的落新妇甙,建立肝左、中叶70%部分肝缺血再灌注模型,模型组和假手术组给予同样体积的生理盐水。小鼠肝脏左叶缺血90min、再灌注6h后各实验组采集血液和肝脏组织样本。Westernblot检测肝组织中SOCS-1、IL-10蛋白含量,半定量RT-PCR检测上述分子mRNA表达情况。结果:落新妇甙小、大剂量干预组肝组织中SOCS-1、IL-10蛋白表达与I/R模型对照组比较均渐次升高,与半定量RT-PCR结果相符(小剂量干预组P＜0.05;大剂量干预组P＜0.01)。结论:落新妇甙干预能促进缺血再灌注损伤肝组织中IL-10蛋白及mRNA在的高表达,从而起到抑制炎症的作用;落新妇甙干预能促进缺血再灌注损伤肝组织SOCS1蛋白和mRNA的表达,显示其可能通过上调SOCS1负调节通路产生抑制炎症的作用。
Experimental Study on the molecular mechanism of the effect of astilbin on liver warm ischemia-reperfusion injury
Liver transplantation has become the method of choice for treatment of the majority of acute and chronic end-stage liver disease.However,ischemia-reperfusion injury(IRI) existing in every case of liver transplantation is still the main reason of primary graft dysfunction or non-function.The shortage of donor leads to the growing use of the marginal donor in most transplant centres,including the aging donor,non-heart-beating donors,small size and fatty liver donor,while the basic problem of the marginal donor is still IRI.So,reducing IRI maximatily would not only increase the appropriate donors,but also allow more patients recovery from liver transplant surgery.And to achieve this desire, firstly,we should understand the mechanisms of I/R injury more fully.
Liver is one of the most sensitive organs to ischemia-reperfusion injury.The activation of sinusoidal endothelial cells,Kupfer cells and neutrophil and the formation of oxygen free radicals plays an important role in the pathological process of ischemia-reperfusion injury.Oxygen free radicals and inflammatory cytokines,adhesion molecules further promote neutrophil activation and aggregation,mediate lipid peroxidation injury process, which eventually lead to liver damage.
The Toll-like receptors(TLRs) found in 1997 play an important role in the disease of infection and inflammation.The TLR-4 signaling pathway was considered to be dominated in the pathophysiological process of heart,kidney and liver IRI.TLR-4 molecule exists in all of hepatic parenchyma,non-parenchymal cells,each group of liver cells has a complete TLR-4 signaling pathway.Activated hepatic non-parenchymal cells(especially Kupffer cells) play an important role in the liver warm ischemia-reperfusion injury through TLR-4 signaling pathway.Activated TLR-4 leads to the activation of NF-κB,which further triggers great increase of inflammatory cytokines such as TNF-a,IL-1,IL-6,et al.Because of the important role of TLR-4 signaling pathway in liver ischemia-reperfusion injury,the purpose of reducing liver IRI by inhibiting this signaling pathway is of enticing prospects. HO-1 is a heat shock protein 32 members.Liver HO-1 was first produced by Kupffer cells. As one of the TLR-4 ligands,it has strong antioxidant,anti-inflammatory function thus protecting liver IRI by inhibiting TLR-4 signaling pathway.
On the other hand,SOCS1 is a negative regulator molecule,which inhibit ILs,IFN-γ, GH,and other cytokine signal transduction pathway through negative regulation of JAK-STAT signaling pathway.SOCS1 also involves in the regulation of other signaling pathways,such as TNF-a,LPS.The over-expression of SOCS1 in vitro can significantly reduce the hepatocytes apoptosis induced by TNF-a,while TNF-a is considered TLR-4 activation marker,implying that SOCS1 may be one of the endogenous negative regulators of TLR-4 signal transduction systems.Studies show that IL-10 can promote the formation of SOCS protein,in particular the SOCS1 and SOCS3.The role of inhibiting inflammation and protecting organizations of IL-10 can be observed in many models of ischemia -reperfusion injury,including liver.So if drugs can promote IL-10 expression in vivo,it could play a protective role in the liver IRI through regulating SOCS1 negative signal pathway.
Astilbin is one of the three flavanonols isolated from the ethanol extract of rhizoma. Flavonoids have strong function of antioxidant and can be used as delivery of hydrogen to scavenging oxygen free radicals,resulting in anti-inflammatory and reducing ischemia-reperfusion injury.Researches have confirmed its role of diuretic,analgesic, anti-inflammatory and reduce myocardial ischemia-reperfusion injury.As reported that astilbin could significantly reduce the liver damage induced by carbon tetrachloride(CC14) through the intervention of oxygen free radicals and lipid peroxide formation;In concanavalin A(Con A)-induced hepatitis,astilbin could significantly reduce TNF-a production and the proliferation of liver Kupffer cells.And in a contact dermatitis model, astilbin could significantly promote the expression of IL-10 and SOCS1 and SOCS3, reducing inflammatory response.
Based on these research backgrounds,further study will be involved in this topic: 1)The protective effects of astilbin on liver warm ischemia-reperfusion injury,including liver function,liver pathology,SOD,MDA,the MPO detection;2) The effects of astilbin on the expression of TLR-4,HO-1,NF-κB,TNF-a protein and mRNA in the liver ischemia-reperfusion injury model,to investigate the molecular mechanisms of inhibiting inflammation signal pathway;3) The effects of astilbin on the expression of IL-10,SOCS1 protein and mRNA,to explore the molecular mechanism of promoting anti-inflammation signaling pathway.Based on these researches,to prepare for the further study on the mechanisms of protective and immunosuppressive effects of astilbin on liver ischemia and reperfusion injury,in the liver transplantation model of allogeneic mice.
PARTⅠ.Effect of astilbin on liver warm ischemia-reperfusion injury
Objective:To investigate the protective effect of astilbin on liver function and hepatic tissues in the liver warm ischemia-reperfusion injury.Methods:C57BL/6 mice were randomly divided into four groups(n=8):sham-operated group(Sham),model control group(I/R),low dosage of astilbin treatment group(10mg/kg) and large dosage of astilbin(40mg/kg) treatment group.24 hours and one hour before Ischemia,treatment group mice were intraperitoneally injected 10 or 40 mg/kg astilbin.Then the hepatic ischemia-reperfusion model of 70 percent of liver,including the left and middle hepatic lobe,were established.The I/R model control group and the sham operation group were administered with the same volume of normal saline.After 90 min ischemia and 6h reperfusion of the partial hepatic lobe,blood and liver tissue samples were collected from the experimental groups.Serum ALT activity was detected as an indicator of liver function damage,and the content of MDA,MPO,SOD in liver tissues were detected by ELISA. Histopathology detection was performed.Results:Compared with the I/R model control group,serum ALT in both treatment group of the low and large dosage astilbin were significantly decreased(P＜0.01),even lower in the large dosage group than in the low dosage group(P＜0.01).Hepatic pathology performance improved significantly in the large dosage group;The content of MDA,MPO in liver tissues were significantly decreased in both treatment groups when compared with the I/R model control group(P＜0.01),also lower in the large dosage group than in the low dosage group(P＜0.01).And SOD levels significantly increased in treatment groups(P＜0.01),higher in the large dosage group than in the low dosage group(P＜0.05).Couclusiou:Treatment with astilbin can effectively improve the mouse liver function and liver pathology damage induced by liver warm ischemia-reperfusion injury;Intervention with astilbin can reduce the aggregation, infiltration and activation of neutrophil in the mouse liver induced by warm ischemia-reperfusion injury,thereby reducing inflammatory response;Intervention with astilbin can inhibit the formation of oxygen free radicals,and reduce the damage of lipid peroxidation induced by liver ischemia-reperfusion injury.
PARTⅡ.Inhibiting Effect of Astilbin on TLR-4 Signaling Pathway in Liver warm ischemia-reperfusion injury
Objective:To study the molecular mechanism of the effect of astilbin on inhibiting the inflammation signaling pathway in liver warm ischemia-reperfusion injury.Methods: C57BL/6 mice were randomly divided into four groups(n=5):sham-operated group (Sham),model control group(I/R),low dosage of astilbin treatment group(10mg/kg) and large dosage of astilbin(40mg/kg) treatment group.24 hours and one hour before Ischemia, treatment group mice were intraperitoneally injected 10 or 40 mg/kg astilbin.Then the hepatic ischemia-reperfusion model of 70 percent of liver,including the left and middle hepatic lobe,were established.The I/R model control group and the sham operation group were administered with the same volume of normal saline.After 90 min ischemia and 6h reperfusion of the partial hepatic lobe,blood and liver tissue samples were collected from the experimental groups.Serum TNF-a activity was detected,and the content of TNF-a、TLR-4、NF-κB and HO-1 in liver tissues were detected by western blot.mRNA expression of these proteins was detected by semiquantitative RT-PCR.Results:Compared with the I/R model control group,serum TNF-a in both treatment group of the low and large dosage astilbin were significantly decreased(P＜0.01),even lower in the large dosage group than in the low dosage group(P＜0.01).The protein content of TNF-a、TLR-4、NF-κB in liver tissues were gradually decreased in both treatment groups when compared with the I/R model control group,also lower in the large dosage group than in the low dosage group. Same trends were observed in the mRNA expression of these proteins showed by semiquantitative RT-PCR(low dosage group P＜0.05;large dosage group P＜0.01).HO-1 levels gradually increased in treatment groups,higher in the large dosage group than in the low dosage group,the result of mRNA showed a same trend(low dosage group P＜0.05; large dosage group P＜0.01).Conclusion:Intervention with astilbin can reduce the high levels of serum TNF-a caused by ischemia-reperfusion injury,as well as increased expression of TNF-a protein and mRNA in the liver tissues,thereby reducing TNF-a-mediated further injury;Intervention with astilbin can reduce the high expression of TLR-4 protein and mRNA,and NF-κB protein in IRI liver tissues,demonstrating its effect of inhibiting TLR-4 inflammation signaling pathway.Treatment with astilbin can promote the expression of HO-1 protein and mRNA in IRI liver,demonstrating its effect of TLR-4 pathway inhibition and promotion of the expression of HO-1 is closely related.
PARTⅢ.Effect of Astilbin on Expression of SOCS1、IL-10 in Liver warm ischemia-reperfusion injury
Objective:To study the molecular mechanism of the effect of astilbin on the anti-inflammation signaling pathway in liver warm ischemia-repeffusion injury.Methods: C57BL/6 mice were randomly divided into four groups(n=5):sham-operated group (Sham),model control group(I/R),low dosage of astilbin treatment group(10mg/kg) and large dosage of astilbin(40mg/kg) treatment group.24 hours and one hour before Ischemia, treatment group mice were intraperitoneally injected 10 or 40 mg/kg astilbin.Then the hepatic ischemia-reperfusion model of 70 percent of liver,including the left and middle hepatic lobe,were established.The I/R model control group and the sham operation group were administered with the same volume of normal saline.After 90 min ischemia and 6h reperfusion of the partial hepatic lobe,liver tissue samples were collected from the experimental groups.The content of SOCS-1 and IL-10 in liver tissues were detected by western blot.mRNA expression of the same proteins was detected by semiquantitative RT-PCR.Results:Compared with the I/R model control group,SOCS-1 and IL-10 protein levels gradually increased in treatment groups,higher in the large dosage group than in the low dosage group,the result of mRNA showed a same trend(low dosage group P＜0.05; large dosage group P＜0.01).Conclusion:Intervention with astilbin can promote the expression of IL-10 protein and mRNA in IRI liver,thus inhibiting the inflammation; Intervention with astilbin can promote the expression of SOCS-1 protein and mRNA in IRI liver,showing its role of negative regulation by upregulating SOCS1 pathway.
引文
1.Busuttil,R.W,Tanaka,K.The utility of marginal donors in liver transplantation.Liver Transplantation.2003,9(7):651-663.
2.Reddy S,Zilvetti M,Brockmann J,et al.Liver transplantation from non-heart-beating donors:current status and future prospects.Liver Transplantation.2004,10(10):1223-1232.
3.Franco-Gou R,Peralta C,Massip-Salcedo M,et al.Protection of reduced-size liver for transplantation.American Journal of Transplantation.2004,4(9):1408-1420.
4. Farmer DG, Amersi F, Kupiec-Weglinski JW, Busuttil RW. Current status of ischemia and reperfusion injury in the liver. Transplant Rev. 2000; 14:106-126.
5. Wu J, Groh V, Spies T. T cell antigen receptor engagement and specificity in the recognition of stress-inducible MHC class I -related chains by human epithelial gamma delta T cells. J Immunol 2002; 169(3):1236-1240.
6. Fondevila C, Busuttil RW, Kupiec-Weglinski JW. Hepatic ischemia/reperfusion injury-a fresh look. Exp Mol Pathol 2003; 74: 86.
7. Teoh NC, Farrell GC. Hepatic ischemia reperfusion injury: Pathogenic mechanisms and basis for hepatoprotection. J Gastroenterol Hepatol 2003; 18: 891.)
8. Farhood A, McGuire GM, Manning AM, et al. Intercellular adhesion molecule I (ICAM-1) expression and its role in neutrophil-induced ischemia-reperfusion injury in rat liver. J Leukoc Biol 1995; 57: 368-374.
9. Gong JP, Wu CX, Liu CA, et al. Liver sinusoidal endothelial cell injury by neutrophils in rats with acute obstructive cholangitis. World J Gastroenterol 2002; 8: 342-348.
10. Nicholas LT, Ronald DG. Efects of initial ischemia/reperfusion injury on the transplanted kidney. Transplantation 1997; 64: 945-947.
11. Oyama J, Blais C Jr, Liu X, et al. Reduced myocardial ischemiareperfusion injury in toll-like receptor 4-deficient mice. Circulation, 2004,109(6): 784-789.
12. Wolfs TG, Buurman WA, van Schadewijk A, et al. In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFN-gamma and TNF-alpha mediated up-regulation during inflammation. J Immunol, 2002, 168(3): 1286-1293.
13. Wu HS, Zhang JX, Wang L, et al. Toll-like receptor 4 involvement in hepatic ischemia/reperfusion injury in mice. Hepatobiliary Pancreat Dis Int, 2004, 3(2): 250-253.
14. Ke B, Shen XD, Gao F, et al. Interleukin 13 Gene Transfer in Liver Ischemia and Reperfusion Injury: Role of Stat6 and TLR4 Pathways in Cytoprotection. Hum Gene Ther, 2004, 15(7): 691-698.
15. Liu S, D. J. Gallo, A. M. Green, et al. Role of Toll-like receptors in changes in gene expression and NF-kB activation in mouse hepatocytes stimulated with lipopolysaccharide. Infect. Immun, 2002, 70: 3433-3442.
16. Su G L, R D Klein, A Aminlari, et al. Kupffer cell activation by lipopolysaccharide in rats: role for lipopolysaccharide binding protein and Toll like receptor 4. Hepatology, 2000, 31: 932-936.
17. Tsung A, R Sahai, H Tanaka, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J. Exp. Med, 2005, 201:1135-1143.
18. Zhai Y, X D Shen, R O'Connell, et al. Cutting edge: TLR-4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J. Immunol, 2004,173: 7115-7119.
19. Allan Tsung, Rosemary A. Hoffman, Kunihiko Izuishi, et al. Hepatic Ischemia/Reperfusion Injury Involves Functional TLR-4 Signaling in Nonparenchymal Cells. The Journal of Immunology, 2005,175: 7661-7668.
20. Chen W, Syldath U, Bellmann K, Kolb H. Human 60-kDa heat shock protein: a danger signal to the innate immune system. J Immunol, 1999,162: 3212-3219.
21. Colleti LM, Cortis A, Lukacs N, et al. Tumor necrosis factor-a up-regulates intercellular adhesion molecule 1, which is important in the neutrophil-dependent lung and liver injury associated with hepatic ischemia and reperfusion in the rat. Shock 1998, 10: 182-191
22. Issekutz TB. Efects of six diferent cytokines on lymphocyte adherence to microvascular endothelium and in-vivo lymphocyte migration in the rat. J Immunol, 1990, 144: 2140-2146
23. Tsujimoto M, Yokota S, Vilcek J, Weissmann G. Tumor necrosis factor provokes superoxide anion generation from neutrophils. Biochem Biophys Res Commun, 1986, 137:1094-1100
24. Meyer JD, Yurt RW, Duhaney R, et al. Tumor necrosis factor enhanced leukotriene B4 generation and chemotaxis in human neutrophils. Arch Surg, 1988,123:1454-1458
25. Yu YY, Si CW, Tian XL, et al. Efect of cytokines on liver necrosis. World J Gastroenterol, 1998,4: 311-313.
26. Zang GQ, Zhou XQ, Yu H, et al. Efect of hepatocyte apoptosis induced by TNF-a on acute severe hepatitis in mouse models. World J Gastroenterol, 2000, 6: 688-692.
27. Konrad S, Ledger L, Danja G Jan R, et al. Tumor necrosis factor in the pathogenesis of human and murine fulminant hepatic failure. Gastroenterology, 2000,119: 446-460
28. Hoshino K, Takeuchi O, Kawai T et al. Cutting edge: toll-like receptor 4 (TLR-4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR-4 as the Lps gene product. J Immunol, 1999,162: 3749-3752.
29. Xiu-Da Shen, Bibo Ke, Yuan Zhai, et al. Toll-Like Receptor and Heme Oxygenase-1 Signaling in Hepatic Ischemia/Reperfusion Injury. American Journal of Transplantation, 2005,5:1793-1800.
30. Chong MM, Thomas HE, Kay TW. Suppressor of cytokine signaling-1 regulates the sensitivity of pancreatic βcells to tumor necrosis factor. J Biol Chem, 2002, 277: 27945-27952.
31. Morita Y, Naka T, Kawazoe Y, et al. Signals transducers and activators of transcription (STAT)-induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor necrosis factor -induced cell death in fibroblasts. Proc Natl Acad Sci USA, 2000, 97:5405-5410.
32. Kinjyo I, Hanada T, Inagaki-Ohara K, et al. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity. 2002,17:583-591.
33. Nakagawa R, Naka T, Tsutsui H, et al. SOCS-1 participates in negative regulation of LPS responses. Immunity. 2002,17:677-687.
34. Gabriele SASS, Noula D. SHEMBADE, Gisa TIEGS. Tumour necrosis factor a (TNF)-TNF receptor 1-inducible cytoprotective proteins in the mouse liver: relevance of suppressors of cytokine signalling. Biochem. J. 2005(385): 537-544.
35. H. Yasukawa, A. Sasaki and A. Yoshimura, Negative regulation of cytokine signaling pathways, Annu Rev Immunol. 2000 (18): 143-164.
36. Sander Dinant, Reeta L.Vetelainen, Sandrine Florquin, et al. IL-10 Attenuates Hepatic I/R Injury and Promotes Hepatocyte Proliferation. Journal of Surgical Research. 2007, 141(2):176-182.
37. R.E. Engles, T.S. Huber, D.S. Zander, et al. Exogenous human recombinant interleukin-10 attenuates hindlimb ischemia-reperfusion injury. J Surg Res. 1997, 69(2): 425-428.
38. MJ. Eppinger, P.A. Ward, S.F. Boiling, et al. Regulatory effects of interleukin-10 on lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 1996,112(5): 1301-1305.
39. O. Le Moine, H. Louis, A. Demols, et al. Cold liver ischemia-reperfusion injury critically depends on liver T cells and is improved by donor pretreatment with interleukin 10 in mice. Hepatology. 2000, 31 (6): 1266-1274.
40. R. Hayward, T.O. Nossuli, R. Scalia. et al. Cardioprotective effect of interleukin-10 in murine myocardial ischemia-reperfusion. Eur J Pharmacol. 1997, 334 (2-3): 157-163.
41. Eiattar TMA, Virji AS. Modulating efect of resveratol and quercetin on oral cancer cell growth and proliferation.Anti-Cancer Drugs,1999;10:187-193.
42.吴丽明,张敏。土茯苓中落新妇甙的利尿和镇痛作用。中药材,1995,18(12):627-630.
43.高思海,潘铁成。落新妇甙的提取及对心肌缺血再灌注损伤的保护作用研究。中华实用中西医杂志,2003,3(16):1693-1694.
44.D.Closa,M.Tones,G.Hotter,et.al.Prostanoids and free radicals in CC14 induced hepatotoxicity in rats:effect of astilbin.Prostaglandins,Leukotrienes and Essential Fatty Acids,1997,56(4),331-334.
45.Jun Wang,Ying Zhao,Qiang Xu.Astilbin prevents concanavalin A-induced liver injury by reducing TNF-a production and T lymphocyte adhesion.JPP,2004,56:495-502.
46.Mingjian Fei,Xuefeng Wu,Qiang Xu.Astilbin inhibits contact hypersensitivity through negative cytokine regulation distinct from cyclosporin A.Journal of Allergy and Clinical Immunology,2005,116(6):1350-1356.
1.Farmer DG,Amersi F,Kupiec-Weglinski JW,Busuttil RW.Current status of ischemia and reperfusion injury in the liver.Transplant Rev.2000;14:106-126.
2.Wu J,Groh V,Spies T.T cell antigen receptor engagement and specificity in the recognition of stress-inducible MHC class Ⅰ-related chains by human epithelial gamma delta T cells.J Immunol 2002;169(3):1236-1240.
3.Fondevila C,Busuttil RW,Kupiec-Weglinski JW.Hepatic ischemia/reperfusion injury-a fresh look.Exp Mol Pathol 2003;74:86.
4.Teoh NC,Farrell GC.Hepatic ischemia reperfusion injury:Pathogenic mechanisms and basis for hepatoprotection.J Gastroenterol Hepatol 2003;18:891.)
5.Farhood A,McGuire GM,Manning AM,et al.Intercellular adhesion molecule Ⅰ(ICAM-1) expression and its role in neutrophil-induced ischemia-reperfusion injury in rat liver.J Leukoc Biol 1995;57:368-374.
6.Gong JP,Wu CX,Liu CA,et al.Liver sinusoidal endothelial cell injury by neutrophils in rats with acute obstructive cholangitis.World J Gastroenterol 2002;8:342-348.
7.Nicholas LT,Ronald DG.Efects of initial ischemia/reperfusion injury on the transplanted kidney.Transplantation 1997;64:945-947.
8.Eiattar TMA,Virji AS.Modulating efect of resveratol and quercetin on oral cancer cell growth and proliferation.Anti-Cancer Drugs,1999;10:187-193.
9.吴丽明,张敏。土茯苓中落新妇甙的利尿和镇痛作用。中药材,1995,18(12):627-630.
10.高思海,潘铁成。落新妇甙的提取及对心肌缺血再灌注损伤的保护作用研究。中华实用中西医杂志,2003,3(16):1693-1694.
11.D.Closa,M.Torres,G.Hotter,et.al.Prostanoids and free radicals in CC14 induced hepatotoxicity in rats:effect of astilbin.Prostaglandins,Leukotrienes and Essential Fatty Acids,1997,56(4),331-334.
12.Zhai Y,Shen X,O'Connell R,et al.Cutting Edge:TLR-4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway.J Immunol 2004;173:7115.
13.Jun Wang,Ying Zhao and Qiang Xu.Astilbin prevents concanavalin A-induced liver injury by reducing TNF-a production and T lymphocyte adhesion.JPP 2004,56:495-502.
14.Mingjian Fei,Xuefeng Wu,Qiang Xu.Astilbin inhibits contact hypersensitivity through negative cytokine regulation distinct from cyclosporin A.Journal of Allergy and Clinical Immunology,2005,116(6):1350-1356.
15.Belzer FO,Southard JH.Principles of solid-organ preservation by cold storage.Transplantation.1988;45:673-676.
16.Teramoto K,BowerJL,Kruskal JB,Clouse ME.Hepatic microcirculatory changes after reperfusion in fatty and normal liver transplantation in the rat.Transplantation.1993;56:1076-1082.
17.Jaeschke H,Farhood A.Neutrophil and Kupfer cell-induced oxidant stress and ischemia-reperfusion injury in rat liver.Am J Physiol 1991;260:G355-G362.
18.Jiang Y,Gu XP,Qiu YD,et al.Ischemic preconditioning decreases C-X-C chemokine expression and neutrophil accumulation early after liver transplantation in rats.World J Gastroenterol 2003;9:2025-2029.
19.Colleti LM,Cortis A,Lukacs N,et al.Tumor necrosis factor-a up-regulates intercellular adhesion molecule 1,which is important in the neutrophil-dependent lung and liver injury associated with hepatic ischemia and reperfusion in the rat.Shock 1998;10:182-191.
20.McCord JM.Oxygen-derived free radicals in postischemic tissue injury.N Engl J Med 1985;312:159-63.
21.Becker LB.New concepts in reactive oxygen species and cardiovascular reperfusion physiology.Cardiov Res 2004;61:461-70.
22.Hess ML,Mason NH.Molecular oxygen:friend and foe.The role of the oxygen free radical system in the calcium paradox,the oxygen paradox and ischemia/reperfusion injury.J Mol Cell Cardiol 1984;16:969-85.
23.陈广耀,沈连生,江佩芬。土茯苓中二氢黄酮醇甙的研究。中国中药杂志,1996;21(6):355-357.
24. Shen XD, Ke B, Zhai Y, et al. Toll-like receptor and heme oxygenase-1 signaling in hepatic ischemia/reperfusion injury. AmJ Transplant 2005 ;5:1793.
25. Zhang WH, Wang JS, Zhou Y, Li JY. Gadolinium chloride and salvia miltiorrhiza compound ameliorate reperfusion injury in hepatocellular mitochondria. World J Gastroenterol. 2003; 9(9): 2040-2044.
26. Gao W, Bently RC, Madden JF. Apoptosis of sinusoidal endothelial cells is a critical mechanism of preservation injury in rat liver transplantation. Hepatology 1998; 27: 1652-1660.
27. Decker K. Biologically active products of stimulated liver macrophages (Kupfer cells). Eur J Biochem 1990; 192: 245-261.
28. Caldwell-Kenkel JC, Currin RT, Tanaka Y et al. Kupfer cell activation and endothelial cell damage after storage of rat liver: effects of reperfusion. Hepatology. 1991; 13: 83-95.
29. Fondevila C, Busutil RW, Kupiec-Weglinski JW. Hepatic ischemia/reperfusion injury-a fresh look. Experimential and Molecular Pathology 2003; 74: 86-93.
30. Tosi MF, Stark JM, Wane C. Inductiong of ICAM-1 expression on human airway epithelial cells by inflammatory cytokines: effect on neutrophil-epithelial adhension [J]. AM J Respir, 1992,7(2):214-221.
31. Bradlay PP, Pkiebat DA, Cristensen RD, et al. Measurement of cutaneous inflammation: estimation of neutrofil content with an enzyme marker [J]. J Invest Dermatol, 1982, 78(3): 206-209.
32. Hines IN, Harada H, Wolf R, Grisham MB. Superoxide and postischemic liver injury: potential therapeutic target for liver transplantation. Curr Med Chem 2003; 10: 2661-7.
33. Wheeler M, Katuna M, Smutney O, Froh M, Dikalova A, Mason R et al. Comparison of the effect of adenoviral delivery of three superoxide dismutase genes against hepatic ischemia-reperfusion injury. Hum Gene Ther 2001; 12: 2167-77.
34. Lehmann TG, Wheeler MD, Froh M, et al. Effects of three superoxide dismutase genes delivered with an adenovirus on graft function after transplantation of fatty livers in the rat. Transplantation 2003; 76: 28-37.
35. Mun KC, Lee HG, Lee TH, Kim YH, Kwak CS, Kim SP, et al. Effect of modified polyhemoglobin on the ischemia/reperfusion injury in kidney. Transplant Proc 2003; 35: 99-100.
36. Chang EJ, Lee SH, Mun KC, Suh SI, Bae JH, Kim SP, et al. Effect of artificial cells on hepatic function after ischemia-reperfusion injury in liver.Transplant Proc 2004;36:1959-61.
1.Oyama J,Blais C Jr,Liu X,et al.Reduced myocardial ischemiareperfusion injury in toll-like receptor 4-deficient mice.Circulation,2004,109(6):784-789.
2.Wolfs TG,Buurman WA,van Schadewijk A,et al.In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells:IFN-gamma and TNF-alpha mediated up-regulation during inflammation.J Immunol,2002,168(3):1286-1293.
3.Wu HS,Zhang JX,Wang L,et al.Toll-like receptor 4 involvement in hepatic ischemia/reperfusion injury in mice.Hepatobiliary Pancreat Dis Int,2004,3(2):250-253.
4.Ke B,Shen XD,Gao F,et al.Interleukin 13 Gene Transfer in Liver Ischemia and Reperfusion Injury:Role of Stat6 and TLR4 Pathways in Cytoprotection.Hum Gene Ther,2004,15(7):691-698.
5. Liu S, D. J. Gallo, A. M. Green, et al. Role of Toll-like receptors in changes in gene expression and NF-kB activation in mouse hepatocytes stimulated with lipopolysaccharide. Infect Immun, 2002,70: 3433-3442.
6. Su, G. L., R. D. Klein, A. Aminlari, et al. Kupffer cell activation by lipopolysaccharide in rats: role for lipopolysaccharide binding protein and Toll like receptor 4. Hepatology, 2000,31: 932-936.
7. Tsung, A., R. Sahai, H. Tanaka, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion.J. Exp. Med, 2005, 201:1135-1143.
8. Zhai, Y., X. D. Shen, R. O'Connell, et al. Cutting edge: TLR-4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway.J. Immunol, 2004,173: 7115-7119.
9. Allan Tsung, Rosemary A. Hoffman, Kunihiko Izuishi, et al. Hepatic Ischemia/Reperfusion Injury Involves Functional TLR-4 Signaling in Nonparenchymal Cells. The Journal of Immunology, 2005,175: 7661-7668.
10. Chen W, Syldath U, Bellmann K, Kolb H. Human 60-kDa heat shock protein: a danger signal to the innate immune system. J Immunol, 1999,162: 3212-3219.
11. Colleti LM, Cortis A, Lukacs N, et al. Tumor necrosis factor-a up-regulates intercellular adhesion molecule 1, which is important in the neutrophil-dependent lung and liver injury associated with hepatic ischemia and reperfusion in the rat. Shock 1998, 10: 182-191
12. Issekutz TB. Efects of six diferent cytokines on lymphocyte adherence to microvascular endothelium and in-vivo lymphocyte migration in the rat. J Immunol, 1990, 144: 2140-2146
13. Tsujimoto M, Yokota S, Vilcek J, Weissmann G. Tumor necrosis factor provokes superoxide anion generation from neutrophils. Biochem Biophys Res Commun, 1986, 137:1094-1100
14. Meyer JD, Yurt RW, Duhaney R, et al. Tumor necrosis factor enhanced leukotriene B4 generation and chemotaxis in human neutrophils. Arch Surg, 1988,123:1454-1458
15. Yu YY, Si CW, Tian XL, et al. Efect of cytokines on liver necrosis. World J Gastroenterol, 1998, 4: 311-313.
16. Zang GQ, Zhou XQ, Yu H, et al. Efect of hepatocyte apoptosis induced by TNF-a on acute severe hepatitis in mouse models. World J Gastroenterol, 2000, 6: 688-692.
17.Konrad S,Ledger L,Danja G Jan R,et al.Tumor necrosis factor in the pathogenesis of human and murine fulminant hepatic failure.Gastroenterology,2000,119:446-460
18.Hoshino K,Takeuchi O,Kawai T et al.Cutting edge:toll-like receptor 4(TLR-4)-deficient mice are hyporesponsive to lipopolysaccharide:evidence for TLR-4 as the Lps gene product.J Immunol,1999,162:3749-3752.
19.Xiu-Da Shen,Bibo Ke,Yuan Zhai,et al.Toll-Like Receptor and Heme Oxygenase-1Signaling in Hepatic Ischemia/Reperfusion Injury.American Journal of Transplantation,2005,5:1793-1800.
20.Jun Wang,Ying Zhao,Qiang Xu.Astilbin prevents concanavalin A-induced liver injury by reducing TNF-a production and T lymphocyte adhesion.JPP,2004,56:495-502.
21.Meldrum K K,Meldrum D R,Meng X,et al.TNF-alpha-dependent bilateral renal injury is induced by unilateral renal ischemia-reperfusion.Am J Physiol Heart Circ Physiol,2002,282(2):H540.
22.Serteser M,Koken T,Kahraman A,et al.Changes in hepatic TNF-alpha levels,antioxidant status,and oxidation products after renal ischemia/reperfusion injury in mice.J Surg Res,2002,107(2):234-240.
23.韩述岭,于立新,马俊杰.抗肿瘤坏死因子-a单克隆抗体减轻肾脏缺血再灌注损伤的实验研究.第一军医大学学报,2003,23(4):332-334.
24.Colletti L M,Kunkel S L,Walz A,et al.The role of cytokine networks in the local liver injury following hepatic ischaemia-reperfusion in the rat.Hepatology,1996,23(3):506-514.
25.Streetz K,Leifeld L,Grundmann D,et al.Tumor necrosis factor a in the pathogenesis of human and murine fulminant hepatic failure.Gastroenterology,2000,119:446-460
26.Hsu H,Xiong J,Goeddel DV.The TNF receptor 1-associated protein TRADD signals cell death and NF-kB activation.Cell,1995,81:495-500.
27.康俊生.肿瘤坏死因子与移植肝的保存再灌注损伤.国外医学生理病理科学与临床分册,1998,18(3):276-278.
28.Yassin M M,Harikin D W,Barros DpSa A A,et al.Lower limb ischemiareperfusion injury triggers a systemic inflammatory response and multiple organ dysfunction.World J Surg,2002,26(1):115-121.
29.Ziv BA,Edith H,Idan B,et al.Role of anti-tumor necrosis factory in ischemia/reperfusion injury in isolated rat liver in a blood-free environment. Transplantation, 2002, 73:1875-188.
30. Tech N, Field J, Suton J, Farrell G. Dual role of tumor necrosis factor-alpha in hepatic ischemia-reperfusion injury: studies in tumor necrosis factor-alpha gene knockout mice. Hepatology, 2004, 39(2): 412-421.
31. Shimazu R, Akashi S, Ogata H et al. MD-2, amolecule that confers lipopolysaccharide responsiveness on toll-like receptor 4. J Exp Med, 1999,189:1777-1782.
32. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparin sulfate by toll-like receptor-4. J Immunol, 2002, 168: 5233-5239.
33. Termmer C, Benedix F, Sleeman J et al. Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med, 2002,195: 99-111.
34. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol, 2001,167: 2287-2292.
35. Basu S, Binder RJ, Suto R, et al. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol, 2000,12:1539-1546.
36. Ohashi K, Burkart V, Floh 'e S, Kolb H. Heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol, 2000,164: 558-561.
37. Asea A, Rehli M, Kabingu E et al. Novel signal transduction pathway utilized by extracellular HSP70. J Biol Chem, 2002, 277:15028-15034.
38. Takahashi Y, Ganster R W, Gambotto A, et al. Role of NF-kappaB on liver cold ischemia reperfusion injury. Am J Physiol Gastrointest Liver Physiol, 2002, 283 (5) : 1175-1184.
39. Fan C, LiQ, Zhang Y, et al. IkappaBalpha and IkappaBbeta possess injury context-specific functions that uniquely influence hepatic NF-kappaB induction and inflammation. J Clin Invest, 2004,113 (5): 746-755.
40. WheelerM D, Yamashina S, FrohM, et al. Adenoviral gene delivery can inactivate Kuffer cell: role of oxidants in NF-kappaB activation and cytokine production. J Leukoe Biol, 2001, 69(4): 622-630.
41. McDonaldM C, Mota-Filipe H, PaulA, et al. Calpain inhibitor I reduces the activation of nuclear factor-kappaB and organ injury/dysfunction in hemorrhagic shock. FASEB J, 2001,15 (1) :171-186.
42. Tsoulfas G, Takahashi Y, Ganster RW, et al. Activation of the lipopolysaccharide signaling pathway in hepatic transplantation preservation injury. Transp lantation, 2002, 74 (1): 7-13.
43. Teoh N, Leclercq I, Pena A D, et al. Low-dose TNF-alpha protects against hepatic ischemia reperfusion injury in mice: imp lications for preconditioning. Hepatology, 2003, 37 (1): 118-128.
44. Gu X P, J iang Y, Xu F T, et al. Effect of cold-ischemia time on nuclear factor-kB activation and inflammatory response in graft after orthotopic liver transplantation in rats. World J Gastroenterol, 2004,10 (7): 1000-1049.
45. Tsuchihashi S, Tamaki T, TanakaM, et al. Pyrrolidine dithiocarbamate provides protection against hypothermic preservation and transplantation injury in the rat liver: the role of heme oxygenase-1. Surgery, 2003,133 (5): 556-567.
46. Suetsugu H, Iimuro Y, Uehara T, et al. Nuclear factor kappaB inactivation in the rat liver ameliorates short term total warm ischaemia / reperfusion injury. Gut, 2005, 54 (6) : 835-842.
47. Yoshidome H, Kato A, EdwardsM J, et al. Interleukin-10 suppresses hepatic ischemia / reperfusion injury in mice: implications of a central role for nuclear factor kappaB. Hepatology, 1999, 30(1): 203-208.
48. Muratore A, Ribero D, Ferrero A, et al. Prospective randomized study of steroids in the prevention of ischaemic injury during hepatic resection with pedicle clamping. Br J Surg, 2003, 90(1): 17-22.
49. Chen W, Syldath U, Bellmann K, Kolb H. Human 60-kDa heatshock protein: a danger signal to the innate immune system. J Immunol, 1999,162: 3212-3219.
50. Ohashi K, Burkart V, Floh 'e S, Kolb H. Heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol, 2000, 164: 558-561.
51. Tsung A, Hoffman RA, Izuishi K, et al. Hepatic ischemia/ reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. J Immunol , 2005 , 175(11) :7661-7668.
52. Bibo KE, Xiu-Da Shen, Sei-ichiro Tsuchihashi, et.al. Viral Interleukin-10 Gene Transfer Prevents Liver Ischemia-Reperfusion Injury: Toll-Like Receptor-4 and Heme Oxygenase-1 Signaling in Innate and Adaptive Immunity. Human Gene Therapy, 2007, 18:355-366.
53. Sei-ichiro Tsuchihashi, Yuan Zhai, Qiao Bo, et.al. Heme Oxygenase-1 Mediated Cytoprotection Against Liver Ischemia and Reperfusion Injury: Inhibition of Type-1 Interferon Signaling. Transplantation, 2007, 83(12): 1628-1634.
1.Chong MM,Thomas HE,Kay TW.Suppressor of cytokine signaling-1 regulates the sensitivity of pancreatic βcells to tumor necrosis factor.J Biol Chem,2002,277:27945-27952.
2.Morita Y,Naka T,Kawazoe Y,et al.Signals transducers and activators of transcription (STAT)-induced STAT inhibitor-1(SSI-1)/suppressor of cytokine signaling-1(SOCS-1)suppresses tumor necrosis factor-induced cell death in fibroblasts.Proc Natl Acad Sci USA,2000,97:5405-5410.
3.Kinjyo I,Hanada T,Inagaki-Ohara K,et al.SOCS1/JAB is a negative regulator of LPS-induced macrophage activation.Immunity.2002,17:583-591.
4.Nakagawa R,Naka T,Tsutsui H,et al.SOCS-1 participates in negative regulation of LPS responses.Immunity.2002,17:677-687.
5.Gabriele SASS,Noula D.SHEMBADE,Gisa TIEGS.Tumour necrosis factor a (TNF)-TNF receptor 1-inducible cytoprotective proteins in the mouse liver:relevance of suppressors of cytokine signalling. Biochem. J. 2005(385): 537-544.
6. H. Yasukawa, A. Sasaki and A. Yoshimura, Negative regulation of cytokine signaling pathways, Annu Rev Immunol. 2000 (18): 143-164.
7. Sander Dinant, Reeta L. Vetelainen, Sandrine Florquin, et al. IL-10 Attenuates Hepatic I/R Injury and Promotes Hepatocyte Proliferation. Journal of Surgical Research. 2007, 141(2):176-182.
8. R.E. Engles, T.S. Huber, D.S. Zander, et al. Exogenous human recombinant interleukin-10 attenuates hindlimb ischemia-reperfusion injury. J Surg Res. 1997, 69(2): 425-428.
9. MJ. Eppinger, P.A. Ward, S.F. Boiling, et al. Regulatory effects of interleukin-10 on lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 1996,112(5): 1301-1305.
10. O. Le Moine, H. Louis, A. Demols, et al. Cold liver ischemia-reperfusion injury critically depends on liver T cells and is improved by donor pretreatment with interleukin 10 in mice. Hepatology. 2000,31 (6): 1266-1274.
11. R. Hayward, T.O. Nossuli, R. Scalia. et al. Cardioprotective effect of interleukin-10 in murine myocardial ischemia-reperfusion. Eur J Pharmacol. 1997,334 (2-3): 157-163.
12. Mingjian Fei, Xuefeng Wu, Qiang Xu. Astilbin inhibits contact hypersensitivity through negative cytokine regulation distinct from cyclosporin A. Journal of Allergy and Clinical Immunology, 2005,116(6): 1350-1356.
13. Alexander W.S, Starr R, Fenner J.E, et, al. SOCS1 is a critical inhibitor of interferon-gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell. 1999, 98: 597-608.
14. Marine J.C, McKay C, Wang D, et, al. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell. 1999, 8: 609-616.
15. Brysha M, Zhang JG, Bertolino P, et al. Suppressor of cytokine signaling-1 attenuates the duration of interferon y signal transduction in vitro and in vivo. J Biol Chem. 2001, 276:22086-22089.
16. Bi XL, Yang JY, Dong YX, et al. Resveratrol inhibits nitric oxide and TNF-alpha production by lipopolysaccharide-activated microglia. Int Immunopharmacol. 2005, 5(1):185-193.
17. Dalpke AH, Opper S, Zimmermann S, et. al. Suppressors of cytokine signaling(SOCS)-1 and SOCS-3 are induced by CpG-DNA and modulate cytokine responses in APCs. J Immunol, 2001,166 (12) :7082-7089.
18. Kinjyo I, Hanada T, Inagaki-Ohara K, et al. SOCS1/ JAB is a negative regulator of LPS-induced macrophage activation. Immunity, 2002,17: 583-591.
19. Guha M, Mack N. LPS induction of gene expression in human monocytes. Cell Signal, 2001,13(2): 85-94.
20. Raimann T, Buschen D, Hipskind RA, et al. Lipopolysaccharide induces activation of the Raf-1 in the induction of the IL-1 beta and the TNF-alpha genes. J Immunol, 1994,153 (12): 5740-5749.
21. Kinjyo I, Hanada T, Inagaki-Ohara K, et al. SOCS1/ JAB is a negative regulator of LPS-induced macrophage activation. Immunity, 2002,17: 583-591.
22. Nakagawa R, Naka T, Tsutsui H, et al. SOCS-1 participates in negative regulation of LPS responses. J Immunity, 2002,17: 677-687.
23. T. Kasama, R.M. Strieter, N.W. Lukacs, et al. Regulation of neutrophil-derived chemokine expression by IL-10. J Immunol. 1994,152 (7): 3559-3569.
24. M.R. de Waal, J. Abrams, B. Bennett, et al. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991,174 (5): 1209-1220.
25. D.F. Fiorentino, A. Zlotnik, T.R. Mosmann, et al. IL-10 inhibits cytokine production by activated macrophages. J Immunol. 1991,147(11): 3815-3822.
26. S. Song, H. Ling-Hu, K.A. Roebuck, et al. Interleukin-10 inhibits interferon-δ-induced intercellular adhesion molecule-1 gene transcription in human monocytes. Blood. 1997, 89 (12): 4461-4469.
27. A.J. Schottelius, M.W. Mayo, R.B. Sartor, et al. Interleukin-10 signaling blocks inhibitor of kB kinase activity and nuclear factor kB DNA binding. J Biol Chem. 1999, 274(45): 31868-31874.
28. J.K. Riley, K. Takeda, S. Akira, et aL Interleukin-10 receptor signaling through the JAK-STAT pathway Requirement for two distinct receptor-derived signals for anti-inflammatory action. J Biol Chem. 1999, 274(23): 16513-16521.
29. Bibo KE, Xiu-Da Shen, Sei-ichiro Tsuchihashi, et.al. Viral Interleukin-10 Gene Transfer Prevents Liver Ischemia-Reperfusion Injury: Toll-Like Receptor-4 and Heme Oxygenase-1 Signaling in Innate and Adaptive Immunity. Human Gene Therapy. 2007,18: 355-366.
1.Busuttil,R.W,Tanaka,K.The utility of marginal donors in liver transplantation.Liver Transplantation.2003,9(7):651-663.
2.Reddy S,Zilvetti M,Brockmann J,et al.Liver transplantation from non-heart-beating donors:current status and future prospects.Liver Transplantation.2004,10(10):1223-1232.
3.Franco-Gou R,Peralta C,Massip-Salcedo M,et al.Protection of reduced-size liver for transplantation.American Journal of Transplantation.2004,4(9):1408-1420.
4.Fondevila C,Busuttil RW,Kupiec-Weglinski JW.Hepatic ischemia/reperfusion injury-a fresh look.Exp Mol Pathol 2003;74:86.
5.Teoh NC,Farrell GC.Hepatic ischemia reperfusion injury:Pathogenic mechanisms and basis for hepatoprotection.J Gastroenterol Hepatol 2003;18:891.
6.Oyama J,Blais C Jr,Liu X,et al.Reduced myocardial ischemiareperfusion injury in toll-like receptor 4-deficient mice.Circulation 2004;109:784.
7.Wolfs TG,Buurman WA,van Schadewijk A,et al.In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells:IFN-gamma and TNF-alpha mediated up-regulation during inflammation.J Immunol 2002;168:1286.
8.Wu HS,Zhang JX,Wang L,et al.Toll-like receptor 4 involvement in hepatic ischemia/reperfusion injury in mice.Hepatobiliary Pancreat Dis Int 2004;3:250.9.Ke B,Shen XD,Gao F,et al.Interleukin 13 Gene Transfer in Liver Ischemia and Reperfusion Injury:Role of Stat6 and TLR4 Pathways in Cytoprotection.Hum Gene Ther 2004;15:691.
10.Yang BR,Mark MR,Gray A,et al.Toll-like receptor-2 mediates lipopolysac—charide-induced cellular signalling.Nature,1998,395(6699):284-288.
11. Kawai T, Adachi O , Ogawit T, et al. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity ,1999,11 (1): 115-122.
12. Takeuchi O , Takeda K, Hoshino K, et al . Cellular responses to bacterial cell wall components are mediated through MyD88-dependent signaling cascades. Int Immunol ,2000,12 (1) :113-117.
13. Thomas JA, Allen JL, Tsen M, et al. Impaired cytokine signaling in mice lacking the IL-1 receptor-associated kinase. J Immunol ,1999 ,163(2) :987-984.
14. Muzio M, Natoli G, Saccani S , et al. The human toll signaling pathway :diver- gence of nuclear factor kappaB and JNK/ SAPK activation upstream of tumor necro—sis factor receptor-associated factor 6 (TRAF6). J Exp Med, 1998,187 (12): 2097-2101.
15. Vogel SN, Johnson D , Perena PY, et al. Cutting edge : functional characteri—zation of the effect of the C3H/ HeJ defect in mice that lack an Lpsn gene : in vivo evidence for a dominant negative mutation. J Immnuol ,1999 ,162 (10) :5666-5670.
16. Qureshi ST ,Lariviere L ,Leveque G,et al. Endotoxin-tolerant mice have muta -tions in toll-like receptor 4 (Tlr4). J Exp Med ,1999 ,189 (4) :615-625.
17. Toshchakov V, Jones BW, Lentschat A, et al. TLR2 and TLR4 agonists stimulate unique repertoires of host resistance genes in murine macrophages-Interferon-beta-dependent signaling in TLR4-mediated responses . J Endotoxin Res 2003; 9: 169.
18. Rhee SH, Jones BW, Toshchakov V, et al. Toll-like receptors 2 and 4 activate STAT1 serine phosphorylation by distinct mechanisms in macrophages. J Biol Chem 2003; 278: 22506.
19. Akira S, Yamamoto M, Takeda K. Role of adapters in Toll-like receptor signal-ling. Biochem Soc Trans 2003; 31: 637.
20. Tamaru M, Nishioji K, Kobayashi Y, et al. Liver-infiltrating T lymphocytesare attracted selectively by IFN-inducible protein-10. Cytokine 2000; 12: 299.
21. Day YJ, Marshall MA, Huang L, et al. Protection from ischemic liver injury by activation of A2A adenosine receptors during reperfusion: Inhibition of chemokine induction. Am J Physiol Gastrointest Liver Physiol 2004; 286: G285.
22. Colletti LM, Green ME, Burdick MD, Strieter RM. The ratio of ELR_to ELR_CXC Chemokines affects the lung and liver injury following hepatic ischemia/ reperfusion in the rat. Hepatology 2000; 31: 435.
23.Asahina Y,Yoshioka N,Kano R,et.al.Full-lenth Cdna cloning of Toll-like receptor 4in dogs and cats.Vet Immunol Immunopathol,2003,96:159-167.
24.Matsumura T,Hayashi H,Takii T.TGF-beta down-regulates IL-1 alpha-induced TLR2expression in murine hepatocytes.J Leukoc Biol,2004,75:1056-1061.
25.Xiong J,Zhu ZH,Liu JS,Wang Y,Wu HS.The expression of toll-like receptor 2,4 of livers in mice with systemic inflammatory response syndrome.Hepatobiliary Pancreat Dis Int.2006;5(1):143-6.
26.Peng Y,Gong JP,Liu CA,et al.Expression of toll-like receptor 4 and MD-2 gene and protein in Kupffer cells after ischemia- reperfusion in rat liver graft.World J Gastroenterol,2004,10(19):2890-2893.
27.Tsung A,Hoffman RA,Izuishi K,et al.Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells.J Immunol,2005,175(11):7661-7668.
28.刘小伟,游宇,卢放根,等.脂多糖信号转导分子TLR4表达与小鼠肝损伤的关系.湖南医科大学学报,2003,28:217-220.
29.Allan Tsung,Rohit Sahai,Hiroyuki Tanaka,et.al.The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion.J Exp Med,2005,201(7):1135-1143.
30.Jun-ichi Oyama,Charles Blais,Jr,Xiaoli Liu,et.al.Reduced Myocardial Ischemia-Reperfusion Injury in Toll-Like Receptor 4-Deficient Mice.Circulation,2004(109):784-789.
31.Bibo KE,Xiu-Da Shen,1 Sei-ichiro Tsuchihashi,et.al.Viral Interleukin-10 Gene Transfer Prevents Liver Ischemia-Reperfusion Injury:Toll-Like Receptor-4 and Heme Oxygenase-1 Signaling in Innate and Adaptive Immunity.Human Gene Therapy,2007,18:355-366.
32.Sei-ichiro Tsuchihashi,Yuan Zhai,Qiao Bo,et.al.Heme Oxygenase-1 Mediated Cytoprotection Against Liver Ischemia and Reperfusion Injury:Inhibition of Type-1Interferon Signaling.Transplantation,2007,83(12):1628-1634.
33.Hui Yin a,Bao-jun Huang a,b,Heng Yang,et.al.Pretreatment with soluble ST2 reduces warm hepatic ischemia/reperfusion injury.Biochemical and Biophysical Research Communications 2006,351:940-946.
34. Greisman, S. E., E. J. Young, and F. A. J. Carozza. Mechanisms of endotoxin tolerance: specificity of the early and late phases of pyrogenic tolerance. J. Immunol. 1969,103: 1223-1236.
35. Tsung, A, R. Sahai, H. Tanaka, et, al. The nuclear factor HMGB1 mediateshepatic injury after murine liver ischemia-reperfusion. J. Exp. Med. 2005(201): 1135-1143.
36. Kunihiko Izuishi, Allan Tsung, Geetha Jeyabalan,et.al. Cutting Edge: High-Mobility Group Box 1 Preconditioning Protects against Liver Ischemia-Reperfusion Injury. The Journal of Immunology, 2006,176: 7154-7158.
37. Fontaine C, Rigamonti E, Nohara A,et.al. Liver X receptor activation potentiates the lipopolysaccharide response in human macrophages. Circ Res, 2007,101(1):40-9.
38. Wu J, Yu P, Hu Z, Zheng S. Statins can be the potential therapeutic agents for reducing infection evoked cholangiopathy after liver transplantation? Med Hypotheses. 2007 Aug 1; Epub ahead of print.
39. Miyaso H, Morimoto Y, Ozaki M,et.al. Protective effects of nafamostat mesilate on liver injury induced by lipopolysaccharide in rats: possible involvement of CD14 and TLR-4 downregulation on Kupffer cells. Dig Dis Sci. 2006, 51(11):2007-12.
40. Tsung A, McCoy SL, Klune JR,et.al. A novel inhibitory peptide of Toll-like receptor signaling limits lipopolysaccharide-induced production of inflammatory mediators and enhances survival in mice. Shock. 2007 Apr;27(4):364-9.
41. Mullarkey M, Rose JR, Bristol J, Kawata T, Kimura A, Kobayashi S, Przetak M, Chow J, Gusovsky F, Christ WJ, Rossignol DP. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther. 2003;304:1093-1102.
42. Akira Shimamoto, Albert J. Chong, Masaki Yada,et.al. Inhibition of Toll-like Receptor 4 With Eritoran Attenuates Myocardial Ischemia-Reperfusion Injury. Circulation 2006;114;I-270-I-274.
1、曹正中。土茯苓化学成分的研究.中草药,1993,24(5):234.
2、陈广耀,沈连生,江佩芬。土茯苓中二氢黄酮醇甙的研究。中国中药杂志,1996:21(6):355-357.
3、Eiattar TMA,Virji AS.Modulating efect of resveratol and quercetin on oral cancer cell growth and proliferation.Anti-Cancer Drugs,1999.10:187-193.
4、吴丽明,张敏。土茯苓中落新妇甙的利尿和镇痛作用。中药材,1995,18(12):627-630.
5、高思海,潘铁成。落新妇甙的提取及对心肌缺血再灌注损伤的保护作用研究。中华实用中西医杂志,2003,3(16):1693-1694.
6、Yan R,Xu Q.Astilbin selectively facilitates the apoptosis of interleukin-2-dependent phytohemagglutinin-activated jurkat cells.Pharmacol Res。2001,44:135-139.
7、高思海,李平,陈涛等。落新妇甙诱导混合细胞培养中活化的T细胞凋亡及其机制。中华器官移植杂志,2006,27(10):580-582.
8、高思海,陈涛,潘铁成.落新妇甙对同种反应性T细胞Bax,Bcl-2和easpase-3表达的影响.中华实用中西医杂志,2003,3(16):2110-2111.
9、高思海,李平,潘铁成.落新妇甙对同种反应性T细胞Fas,FasL和TNF-R1和TNF-R2基因表达的调控.中华实用中西医杂志,2004,4(17):217-218.
10、高思海,李平,陈涛等。落新妇甙对心脏移植效应性T细胞磷脂酰肌醇信号通路的影响。中华胸心血管外科杂志,2007,23(1):47-49.
11、Lafont V,Astoul E,Laurence A,et al.The T cell antigen receptor activates phosphatidylinositol 3-kinase-regulated serine kinases protein kinase B and ribosomal $6kinase 1.FEBS Lett,2000,486:38-42.
12、高思海,陈涛,潘铁成等。落新妇甙对心脏移植排斥反应中活化T细胞穿孔素和颗粒酶B表达的影响。中国医师杂志。2006,8(10):1336-1338.
13、陈涛,潘铁成,高思海等。落新妇甙对小鼠心脏移植排斥反应的抑制作用。山东医药,2006,46(33):7-8.
14、高思海,李平,陈涛等。落新妇甙对心脏移植排斥反应中细胞因子表达的影响。中华小儿外科杂志,2006,27(2):87-89.
15、徐广全,王斌,金相元,等.塞来昔布对大鼠心脏移植急性排斥反应的抑制作用[J].中华器官移植杂志,2006,27(2):105-106.
16、Z.L.Sun,T.Wada,et al.Role of Fas/Fasl in Kupffer cell-dependent deletion of alloantigen activated T cells following liver transplantation.Transplantation Proceedings.2001;33:279-282.
17、Xiao Yang Wang,Junhong Sun,et al.Effect of liver transplantation on islet allografts.Transplantation.2001;71(1):102-111.
18、J.Sun,X.Wang,et al.Increased Fas ligand expression and activated T-lymphocyte apoptosis in islet graft tolerance induced by liver transplantation. Transplantation Proceedings. 2001;33:227-228.
19 Wei Li, Lina LU, et al. IL-12 antagonism enhances apoptotic death of T cells within hepatic allografts from Flt3 ligand-treated donors and promotes graft acceptance. J. Immunol. 2001;166:5619-5628.
20 Wei Li, Lina LU, et al. Costimulation blockade promotes the apoptotic death of graft-infiltrating T cells and prolongs survival of hepatic allografts from Flt3 ligand-treated donors. Transplantation. 2001;72(8):1423-1432.
21 Xu Q, Wu F, Cap J, et al. Astilbin selectivelyinduces dysfunction of liver infiltrating cells—novel protection from liver damage. Eur J Pharm acol, 1999, 377: 93-100.
2.Reddy S,Zilvetti M,Brockmann J,et al.Liver transplantation from non-heart-beating donors:current status and future prospects.Liver Transplantation.2004,10(10):1223-1232.
3.Franco-Gou R,Peralta C,Massip-Salcedo M,et al.Protection of reduced-size liver for transplantation.American Journal of Transplantation.2004,4(9):1408-1420.
4. Farmer DG, Amersi F, Kupiec-Weglinski JW, Busuttil RW. Current status of ischemia and reperfusion injury in the liver. Transplant Rev. 2000; 14:106-126.
5. Wu J, Groh V, Spies T. T cell antigen receptor engagement and specificity in the recognition of stress-inducible MHC class I -related chains by human epithelial gamma delta T cells. J Immunol 2002; 169(3):1236-1240.
6. Fondevila C, Busuttil RW, Kupiec-Weglinski JW. Hepatic ischemia/reperfusion injury-a fresh look. Exp Mol Pathol 2003; 74: 86.
7. Teoh NC, Farrell GC. Hepatic ischemia reperfusion injury: Pathogenic mechanisms and basis for hepatoprotection. J Gastroenterol Hepatol 2003; 18: 891.)
8. Farhood A, McGuire GM, Manning AM, et al. Intercellular adhesion molecule I (ICAM-1) expression and its role in neutrophil-induced ischemia-reperfusion injury in rat liver. J Leukoc Biol 1995; 57: 368-374.
9. Gong JP, Wu CX, Liu CA, et al. Liver sinusoidal endothelial cell injury by neutrophils in rats with acute obstructive cholangitis. World J Gastroenterol 2002; 8: 342-348.
10. Nicholas LT, Ronald DG. Efects of initial ischemia/reperfusion injury on the transplanted kidney. Transplantation 1997; 64: 945-947.
11. Oyama J, Blais C Jr, Liu X, et al. Reduced myocardial ischemiareperfusion injury in toll-like receptor 4-deficient mice. Circulation, 2004,109(6): 784-789.
12. Wolfs TG, Buurman WA, van Schadewijk A, et al. In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFN-gamma and TNF-alpha mediated up-regulation during inflammation. J Immunol, 2002, 168(3): 1286-1293.
13. Wu HS, Zhang JX, Wang L, et al. Toll-like receptor 4 involvement in hepatic ischemia/reperfusion injury in mice. Hepatobiliary Pancreat Dis Int, 2004, 3(2): 250-253.
14. Ke B, Shen XD, Gao F, et al. Interleukin 13 Gene Transfer in Liver Ischemia and Reperfusion Injury: Role of Stat6 and TLR4 Pathways in Cytoprotection. Hum Gene Ther, 2004, 15(7): 691-698.
15. Liu S, D. J. Gallo, A. M. Green, et al. Role of Toll-like receptors in changes in gene expression and NF-kB activation in mouse hepatocytes stimulated with lipopolysaccharide. Infect. Immun, 2002, 70: 3433-3442.
16. Su G L, R D Klein, A Aminlari, et al. Kupffer cell activation by lipopolysaccharide in rats: role for lipopolysaccharide binding protein and Toll like receptor 4. Hepatology, 2000, 31: 932-936.
17. Tsung A, R Sahai, H Tanaka, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J. Exp. Med, 2005, 201:1135-1143.
18. Zhai Y, X D Shen, R O'Connell, et al. Cutting edge: TLR-4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J. Immunol, 2004,173: 7115-7119.
19. Allan Tsung, Rosemary A. Hoffman, Kunihiko Izuishi, et al. Hepatic Ischemia/Reperfusion Injury Involves Functional TLR-4 Signaling in Nonparenchymal Cells. The Journal of Immunology, 2005,175: 7661-7668.
20. Chen W, Syldath U, Bellmann K, Kolb H. Human 60-kDa heat shock protein: a danger signal to the innate immune system. J Immunol, 1999,162: 3212-3219.
21. Colleti LM, Cortis A, Lukacs N, et al. Tumor necrosis factor-a up-regulates intercellular adhesion molecule 1, which is important in the neutrophil-dependent lung and liver injury associated with hepatic ischemia and reperfusion in the rat. Shock 1998, 10: 182-191
22. Issekutz TB. Efects of six diferent cytokines on lymphocyte adherence to microvascular endothelium and in-vivo lymphocyte migration in the rat. J Immunol, 1990, 144: 2140-2146
23. Tsujimoto M, Yokota S, Vilcek J, Weissmann G. Tumor necrosis factor provokes superoxide anion generation from neutrophils. Biochem Biophys Res Commun, 1986, 137:1094-1100
24. Meyer JD, Yurt RW, Duhaney R, et al. Tumor necrosis factor enhanced leukotriene B4 generation and chemotaxis in human neutrophils. Arch Surg, 1988,123:1454-1458
25. Yu YY, Si CW, Tian XL, et al. Efect of cytokines on liver necrosis. World J Gastroenterol, 1998,4: 311-313.
26. Zang GQ, Zhou XQ, Yu H, et al. Efect of hepatocyte apoptosis induced by TNF-a on acute severe hepatitis in mouse models. World J Gastroenterol, 2000, 6: 688-692.
27. Konrad S, Ledger L, Danja G Jan R, et al. Tumor necrosis factor in the pathogenesis of human and murine fulminant hepatic failure. Gastroenterology, 2000,119: 446-460
28. Hoshino K, Takeuchi O, Kawai T et al. Cutting edge: toll-like receptor 4 (TLR-4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR-4 as the Lps gene product. J Immunol, 1999,162: 3749-3752.
29. Xiu-Da Shen, Bibo Ke, Yuan Zhai, et al. Toll-Like Receptor and Heme Oxygenase-1 Signaling in Hepatic Ischemia/Reperfusion Injury. American Journal of Transplantation, 2005,5:1793-1800.
30. Chong MM, Thomas HE, Kay TW. Suppressor of cytokine signaling-1 regulates the sensitivity of pancreatic βcells to tumor necrosis factor. J Biol Chem, 2002, 277: 27945-27952.
31. Morita Y, Naka T, Kawazoe Y, et al. Signals transducers and activators of transcription (STAT)-induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor necrosis factor -induced cell death in fibroblasts. Proc Natl Acad Sci USA, 2000, 97:5405-5410.
32. Kinjyo I, Hanada T, Inagaki-Ohara K, et al. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity. 2002,17:583-591.
33. Nakagawa R, Naka T, Tsutsui H, et al. SOCS-1 participates in negative regulation of LPS responses. Immunity. 2002,17:677-687.
34. Gabriele SASS, Noula D. SHEMBADE, Gisa TIEGS. Tumour necrosis factor a (TNF)-TNF receptor 1-inducible cytoprotective proteins in the mouse liver: relevance of suppressors of cytokine signalling. Biochem. J. 2005(385): 537-544.
35. H. Yasukawa, A. Sasaki and A. Yoshimura, Negative regulation of cytokine signaling pathways, Annu Rev Immunol. 2000 (18): 143-164.
36. Sander Dinant, Reeta L.Vetelainen, Sandrine Florquin, et al. IL-10 Attenuates Hepatic I/R Injury and Promotes Hepatocyte Proliferation. Journal of Surgical Research. 2007, 141(2):176-182.
37. R.E. Engles, T.S. Huber, D.S. Zander, et al. Exogenous human recombinant interleukin-10 attenuates hindlimb ischemia-reperfusion injury. J Surg Res. 1997, 69(2): 425-428.
38. MJ. Eppinger, P.A. Ward, S.F. Boiling, et al. Regulatory effects of interleukin-10 on lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 1996,112(5): 1301-1305.
39. O. Le Moine, H. Louis, A. Demols, et al. Cold liver ischemia-reperfusion injury critically depends on liver T cells and is improved by donor pretreatment with interleukin 10 in mice. Hepatology. 2000, 31 (6): 1266-1274.
40. R. Hayward, T.O. Nossuli, R. Scalia. et al. Cardioprotective effect of interleukin-10 in murine myocardial ischemia-reperfusion. Eur J Pharmacol. 1997, 334 (2-3): 157-163.
41. Eiattar TMA, Virji AS. Modulating efect of resveratol and quercetin on oral cancer cell growth and proliferation.Anti-Cancer Drugs,1999;10:187-193.
42.吴丽明,张敏。土茯苓中落新妇甙的利尿和镇痛作用。中药材,1995,18(12):627-630.
43.高思海,潘铁成。落新妇甙的提取及对心肌缺血再灌注损伤的保护作用研究。中华实用中西医杂志,2003,3(16):1693-1694.
44.D.Closa,M.Tones,G.Hotter,et.al.Prostanoids and free radicals in CC14 induced hepatotoxicity in rats:effect of astilbin.Prostaglandins,Leukotrienes and Essential Fatty Acids,1997,56(4),331-334.
45.Jun Wang,Ying Zhao,Qiang Xu.Astilbin prevents concanavalin A-induced liver injury by reducing TNF-a production and T lymphocyte adhesion.JPP,2004,56:495-502.
46.Mingjian Fei,Xuefeng Wu,Qiang Xu.Astilbin inhibits contact hypersensitivity through negative cytokine regulation distinct from cyclosporin A.Journal of Allergy and Clinical Immunology,2005,116(6):1350-1356.
1.Farmer DG,Amersi F,Kupiec-Weglinski JW,Busuttil RW.Current status of ischemia and reperfusion injury in the liver.Transplant Rev.2000;14:106-126.
2.Wu J,Groh V,Spies T.T cell antigen receptor engagement and specificity in the recognition of stress-inducible MHC class Ⅰ-related chains by human epithelial gamma delta T cells.J Immunol 2002;169(3):1236-1240.
3.Fondevila C,Busuttil RW,Kupiec-Weglinski JW.Hepatic ischemia/reperfusion injury-a fresh look.Exp Mol Pathol 2003;74:86.
4.Teoh NC,Farrell GC.Hepatic ischemia reperfusion injury:Pathogenic mechanisms and basis for hepatoprotection.J Gastroenterol Hepatol 2003;18:891.)
5.Farhood A,McGuire GM,Manning AM,et al.Intercellular adhesion molecule Ⅰ(ICAM-1) expression and its role in neutrophil-induced ischemia-reperfusion injury in rat liver.J Leukoc Biol 1995;57:368-374.
6.Gong JP,Wu CX,Liu CA,et al.Liver sinusoidal endothelial cell injury by neutrophils in rats with acute obstructive cholangitis.World J Gastroenterol 2002;8:342-348.
7.Nicholas LT,Ronald DG.Efects of initial ischemia/reperfusion injury on the transplanted kidney.Transplantation 1997;64:945-947.
8.Eiattar TMA,Virji AS.Modulating efect of resveratol and quercetin on oral cancer cell growth and proliferation.Anti-Cancer Drugs,1999;10:187-193.
9.吴丽明,张敏。土茯苓中落新妇甙的利尿和镇痛作用。中药材,1995,18(12):627-630.
10.高思海,潘铁成。落新妇甙的提取及对心肌缺血再灌注损伤的保护作用研究。中华实用中西医杂志,2003,3(16):1693-1694.
11.D.Closa,M.Torres,G.Hotter,et.al.Prostanoids and free radicals in CC14 induced hepatotoxicity in rats:effect of astilbin.Prostaglandins,Leukotrienes and Essential Fatty Acids,1997,56(4),331-334.
12.Zhai Y,Shen X,O'Connell R,et al.Cutting Edge:TLR-4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway.J Immunol 2004;173:7115.
13.Jun Wang,Ying Zhao and Qiang Xu.Astilbin prevents concanavalin A-induced liver injury by reducing TNF-a production and T lymphocyte adhesion.JPP 2004,56:495-502.
14.Mingjian Fei,Xuefeng Wu,Qiang Xu.Astilbin inhibits contact hypersensitivity through negative cytokine regulation distinct from cyclosporin A.Journal of Allergy and Clinical Immunology,2005,116(6):1350-1356.
15.Belzer FO,Southard JH.Principles of solid-organ preservation by cold storage.Transplantation.1988;45:673-676.
16.Teramoto K,BowerJL,Kruskal JB,Clouse ME.Hepatic microcirculatory changes after reperfusion in fatty and normal liver transplantation in the rat.Transplantation.1993;56:1076-1082.
17.Jaeschke H,Farhood A.Neutrophil and Kupfer cell-induced oxidant stress and ischemia-reperfusion injury in rat liver.Am J Physiol 1991;260:G355-G362.
18.Jiang Y,Gu XP,Qiu YD,et al.Ischemic preconditioning decreases C-X-C chemokine expression and neutrophil accumulation early after liver transplantation in rats.World J Gastroenterol 2003;9:2025-2029.
19.Colleti LM,Cortis A,Lukacs N,et al.Tumor necrosis factor-a up-regulates intercellular adhesion molecule 1,which is important in the neutrophil-dependent lung and liver injury associated with hepatic ischemia and reperfusion in the rat.Shock 1998;10:182-191.
20.McCord JM.Oxygen-derived free radicals in postischemic tissue injury.N Engl J Med 1985;312:159-63.
21.Becker LB.New concepts in reactive oxygen species and cardiovascular reperfusion physiology.Cardiov Res 2004;61:461-70.
22.Hess ML,Mason NH.Molecular oxygen:friend and foe.The role of the oxygen free radical system in the calcium paradox,the oxygen paradox and ischemia/reperfusion injury.J Mol Cell Cardiol 1984;16:969-85.
23.陈广耀,沈连生,江佩芬。土茯苓中二氢黄酮醇甙的研究。中国中药杂志,1996;21(6):355-357.
24. Shen XD, Ke B, Zhai Y, et al. Toll-like receptor and heme oxygenase-1 signaling in hepatic ischemia/reperfusion injury. AmJ Transplant 2005 ;5:1793.
25. Zhang WH, Wang JS, Zhou Y, Li JY. Gadolinium chloride and salvia miltiorrhiza compound ameliorate reperfusion injury in hepatocellular mitochondria. World J Gastroenterol. 2003; 9(9): 2040-2044.
26. Gao W, Bently RC, Madden JF. Apoptosis of sinusoidal endothelial cells is a critical mechanism of preservation injury in rat liver transplantation. Hepatology 1998; 27: 1652-1660.
27. Decker K. Biologically active products of stimulated liver macrophages (Kupfer cells). Eur J Biochem 1990; 192: 245-261.
28. Caldwell-Kenkel JC, Currin RT, Tanaka Y et al. Kupfer cell activation and endothelial cell damage after storage of rat liver: effects of reperfusion. Hepatology. 1991; 13: 83-95.
29. Fondevila C, Busutil RW, Kupiec-Weglinski JW. Hepatic ischemia/reperfusion injury-a fresh look. Experimential and Molecular Pathology 2003; 74: 86-93.
30. Tosi MF, Stark JM, Wane C. Inductiong of ICAM-1 expression on human airway epithelial cells by inflammatory cytokines: effect on neutrophil-epithelial adhension [J]. AM J Respir, 1992,7(2):214-221.
31. Bradlay PP, Pkiebat DA, Cristensen RD, et al. Measurement of cutaneous inflammation: estimation of neutrofil content with an enzyme marker [J]. J Invest Dermatol, 1982, 78(3): 206-209.
32. Hines IN, Harada H, Wolf R, Grisham MB. Superoxide and postischemic liver injury: potential therapeutic target for liver transplantation. Curr Med Chem 2003; 10: 2661-7.
33. Wheeler M, Katuna M, Smutney O, Froh M, Dikalova A, Mason R et al. Comparison of the effect of adenoviral delivery of three superoxide dismutase genes against hepatic ischemia-reperfusion injury. Hum Gene Ther 2001; 12: 2167-77.
34. Lehmann TG, Wheeler MD, Froh M, et al. Effects of three superoxide dismutase genes delivered with an adenovirus on graft function after transplantation of fatty livers in the rat. Transplantation 2003; 76: 28-37.
35. Mun KC, Lee HG, Lee TH, Kim YH, Kwak CS, Kim SP, et al. Effect of modified polyhemoglobin on the ischemia/reperfusion injury in kidney. Transplant Proc 2003; 35: 99-100.
36. Chang EJ, Lee SH, Mun KC, Suh SI, Bae JH, Kim SP, et al. Effect of artificial cells on hepatic function after ischemia-reperfusion injury in liver.Transplant Proc 2004;36:1959-61.
1.Oyama J,Blais C Jr,Liu X,et al.Reduced myocardial ischemiareperfusion injury in toll-like receptor 4-deficient mice.Circulation,2004,109(6):784-789.
2.Wolfs TG,Buurman WA,van Schadewijk A,et al.In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells:IFN-gamma and TNF-alpha mediated up-regulation during inflammation.J Immunol,2002,168(3):1286-1293.
3.Wu HS,Zhang JX,Wang L,et al.Toll-like receptor 4 involvement in hepatic ischemia/reperfusion injury in mice.Hepatobiliary Pancreat Dis Int,2004,3(2):250-253.
4.Ke B,Shen XD,Gao F,et al.Interleukin 13 Gene Transfer in Liver Ischemia and Reperfusion Injury:Role of Stat6 and TLR4 Pathways in Cytoprotection.Hum Gene Ther,2004,15(7):691-698.
5. Liu S, D. J. Gallo, A. M. Green, et al. Role of Toll-like receptors in changes in gene expression and NF-kB activation in mouse hepatocytes stimulated with lipopolysaccharide. Infect Immun, 2002,70: 3433-3442.
6. Su, G. L., R. D. Klein, A. Aminlari, et al. Kupffer cell activation by lipopolysaccharide in rats: role for lipopolysaccharide binding protein and Toll like receptor 4. Hepatology, 2000,31: 932-936.
7. Tsung, A., R. Sahai, H. Tanaka, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion.J. Exp. Med, 2005, 201:1135-1143.
8. Zhai, Y., X. D. Shen, R. O'Connell, et al. Cutting edge: TLR-4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway.J. Immunol, 2004,173: 7115-7119.
9. Allan Tsung, Rosemary A. Hoffman, Kunihiko Izuishi, et al. Hepatic Ischemia/Reperfusion Injury Involves Functional TLR-4 Signaling in Nonparenchymal Cells. The Journal of Immunology, 2005,175: 7661-7668.
10. Chen W, Syldath U, Bellmann K, Kolb H. Human 60-kDa heat shock protein: a danger signal to the innate immune system. J Immunol, 1999,162: 3212-3219.
11. Colleti LM, Cortis A, Lukacs N, et al. Tumor necrosis factor-a up-regulates intercellular adhesion molecule 1, which is important in the neutrophil-dependent lung and liver injury associated with hepatic ischemia and reperfusion in the rat. Shock 1998, 10: 182-191
12. Issekutz TB. Efects of six diferent cytokines on lymphocyte adherence to microvascular endothelium and in-vivo lymphocyte migration in the rat. J Immunol, 1990, 144: 2140-2146
13. Tsujimoto M, Yokota S, Vilcek J, Weissmann G. Tumor necrosis factor provokes superoxide anion generation from neutrophils. Biochem Biophys Res Commun, 1986, 137:1094-1100
14. Meyer JD, Yurt RW, Duhaney R, et al. Tumor necrosis factor enhanced leukotriene B4 generation and chemotaxis in human neutrophils. Arch Surg, 1988,123:1454-1458
15. Yu YY, Si CW, Tian XL, et al. Efect of cytokines on liver necrosis. World J Gastroenterol, 1998, 4: 311-313.
16. Zang GQ, Zhou XQ, Yu H, et al. Efect of hepatocyte apoptosis induced by TNF-a on acute severe hepatitis in mouse models. World J Gastroenterol, 2000, 6: 688-692.
17.Konrad S,Ledger L,Danja G Jan R,et al.Tumor necrosis factor in the pathogenesis of human and murine fulminant hepatic failure.Gastroenterology,2000,119:446-460
18.Hoshino K,Takeuchi O,Kawai T et al.Cutting edge:toll-like receptor 4(TLR-4)-deficient mice are hyporesponsive to lipopolysaccharide:evidence for TLR-4 as the Lps gene product.J Immunol,1999,162:3749-3752.
19.Xiu-Da Shen,Bibo Ke,Yuan Zhai,et al.Toll-Like Receptor and Heme Oxygenase-1Signaling in Hepatic Ischemia/Reperfusion Injury.American Journal of Transplantation,2005,5:1793-1800.
20.Jun Wang,Ying Zhao,Qiang Xu.Astilbin prevents concanavalin A-induced liver injury by reducing TNF-a production and T lymphocyte adhesion.JPP,2004,56:495-502.
21.Meldrum K K,Meldrum D R,Meng X,et al.TNF-alpha-dependent bilateral renal injury is induced by unilateral renal ischemia-reperfusion.Am J Physiol Heart Circ Physiol,2002,282(2):H540.
22.Serteser M,Koken T,Kahraman A,et al.Changes in hepatic TNF-alpha levels,antioxidant status,and oxidation products after renal ischemia/reperfusion injury in mice.J Surg Res,2002,107(2):234-240.
23.韩述岭,于立新,马俊杰.抗肿瘤坏死因子-a单克隆抗体减轻肾脏缺血再灌注损伤的实验研究.第一军医大学学报,2003,23(4):332-334.
24.Colletti L M,Kunkel S L,Walz A,et al.The role of cytokine networks in the local liver injury following hepatic ischaemia-reperfusion in the rat.Hepatology,1996,23(3):506-514.
25.Streetz K,Leifeld L,Grundmann D,et al.Tumor necrosis factor a in the pathogenesis of human and murine fulminant hepatic failure.Gastroenterology,2000,119:446-460
26.Hsu H,Xiong J,Goeddel DV.The TNF receptor 1-associated protein TRADD signals cell death and NF-kB activation.Cell,1995,81:495-500.
27.康俊生.肿瘤坏死因子与移植肝的保存再灌注损伤.国外医学生理病理科学与临床分册,1998,18(3):276-278.
28.Yassin M M,Harikin D W,Barros DpSa A A,et al.Lower limb ischemiareperfusion injury triggers a systemic inflammatory response and multiple organ dysfunction.World J Surg,2002,26(1):115-121.
29.Ziv BA,Edith H,Idan B,et al.Role of anti-tumor necrosis factory in ischemia/reperfusion injury in isolated rat liver in a blood-free environment. Transplantation, 2002, 73:1875-188.
30. Tech N, Field J, Suton J, Farrell G. Dual role of tumor necrosis factor-alpha in hepatic ischemia-reperfusion injury: studies in tumor necrosis factor-alpha gene knockout mice. Hepatology, 2004, 39(2): 412-421.
31. Shimazu R, Akashi S, Ogata H et al. MD-2, amolecule that confers lipopolysaccharide responsiveness on toll-like receptor 4. J Exp Med, 1999,189:1777-1782.
32. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparin sulfate by toll-like receptor-4. J Immunol, 2002, 168: 5233-5239.
33. Termmer C, Benedix F, Sleeman J et al. Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med, 2002,195: 99-111.
34. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol, 2001,167: 2287-2292.
35. Basu S, Binder RJ, Suto R, et al. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol, 2000,12:1539-1546.
36. Ohashi K, Burkart V, Floh 'e S, Kolb H. Heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol, 2000,164: 558-561.
37. Asea A, Rehli M, Kabingu E et al. Novel signal transduction pathway utilized by extracellular HSP70. J Biol Chem, 2002, 277:15028-15034.
38. Takahashi Y, Ganster R W, Gambotto A, et al. Role of NF-kappaB on liver cold ischemia reperfusion injury. Am J Physiol Gastrointest Liver Physiol, 2002, 283 (5) : 1175-1184.
39. Fan C, LiQ, Zhang Y, et al. IkappaBalpha and IkappaBbeta possess injury context-specific functions that uniquely influence hepatic NF-kappaB induction and inflammation. J Clin Invest, 2004,113 (5): 746-755.
40. WheelerM D, Yamashina S, FrohM, et al. Adenoviral gene delivery can inactivate Kuffer cell: role of oxidants in NF-kappaB activation and cytokine production. J Leukoe Biol, 2001, 69(4): 622-630.
41. McDonaldM C, Mota-Filipe H, PaulA, et al. Calpain inhibitor I reduces the activation of nuclear factor-kappaB and organ injury/dysfunction in hemorrhagic shock. FASEB J, 2001,15 (1) :171-186.
42. Tsoulfas G, Takahashi Y, Ganster RW, et al. Activation of the lipopolysaccharide signaling pathway in hepatic transplantation preservation injury. Transp lantation, 2002, 74 (1): 7-13.
43. Teoh N, Leclercq I, Pena A D, et al. Low-dose TNF-alpha protects against hepatic ischemia reperfusion injury in mice: imp lications for preconditioning. Hepatology, 2003, 37 (1): 118-128.
44. Gu X P, J iang Y, Xu F T, et al. Effect of cold-ischemia time on nuclear factor-kB activation and inflammatory response in graft after orthotopic liver transplantation in rats. World J Gastroenterol, 2004,10 (7): 1000-1049.
45. Tsuchihashi S, Tamaki T, TanakaM, et al. Pyrrolidine dithiocarbamate provides protection against hypothermic preservation and transplantation injury in the rat liver: the role of heme oxygenase-1. Surgery, 2003,133 (5): 556-567.
46. Suetsugu H, Iimuro Y, Uehara T, et al. Nuclear factor kappaB inactivation in the rat liver ameliorates short term total warm ischaemia / reperfusion injury. Gut, 2005, 54 (6) : 835-842.
47. Yoshidome H, Kato A, EdwardsM J, et al. Interleukin-10 suppresses hepatic ischemia / reperfusion injury in mice: implications of a central role for nuclear factor kappaB. Hepatology, 1999, 30(1): 203-208.
48. Muratore A, Ribero D, Ferrero A, et al. Prospective randomized study of steroids in the prevention of ischaemic injury during hepatic resection with pedicle clamping. Br J Surg, 2003, 90(1): 17-22.
49. Chen W, Syldath U, Bellmann K, Kolb H. Human 60-kDa heatshock protein: a danger signal to the innate immune system. J Immunol, 1999,162: 3212-3219.
50. Ohashi K, Burkart V, Floh 'e S, Kolb H. Heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol, 2000, 164: 558-561.
51. Tsung A, Hoffman RA, Izuishi K, et al. Hepatic ischemia/ reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. J Immunol , 2005 , 175(11) :7661-7668.
52. Bibo KE, Xiu-Da Shen, Sei-ichiro Tsuchihashi, et.al. Viral Interleukin-10 Gene Transfer Prevents Liver Ischemia-Reperfusion Injury: Toll-Like Receptor-4 and Heme Oxygenase-1 Signaling in Innate and Adaptive Immunity. Human Gene Therapy, 2007, 18:355-366.
53. Sei-ichiro Tsuchihashi, Yuan Zhai, Qiao Bo, et.al. Heme Oxygenase-1 Mediated Cytoprotection Against Liver Ischemia and Reperfusion Injury: Inhibition of Type-1 Interferon Signaling. Transplantation, 2007, 83(12): 1628-1634.
1.Chong MM,Thomas HE,Kay TW.Suppressor of cytokine signaling-1 regulates the sensitivity of pancreatic βcells to tumor necrosis factor.J Biol Chem,2002,277:27945-27952.
2.Morita Y,Naka T,Kawazoe Y,et al.Signals transducers and activators of transcription (STAT)-induced STAT inhibitor-1(SSI-1)/suppressor of cytokine signaling-1(SOCS-1)suppresses tumor necrosis factor-induced cell death in fibroblasts.Proc Natl Acad Sci USA,2000,97:5405-5410.
3.Kinjyo I,Hanada T,Inagaki-Ohara K,et al.SOCS1/JAB is a negative regulator of LPS-induced macrophage activation.Immunity.2002,17:583-591.
4.Nakagawa R,Naka T,Tsutsui H,et al.SOCS-1 participates in negative regulation of LPS responses.Immunity.2002,17:677-687.
5.Gabriele SASS,Noula D.SHEMBADE,Gisa TIEGS.Tumour necrosis factor a (TNF)-TNF receptor 1-inducible cytoprotective proteins in the mouse liver:relevance of suppressors of cytokine signalling. Biochem. J. 2005(385): 537-544.
6. H. Yasukawa, A. Sasaki and A. Yoshimura, Negative regulation of cytokine signaling pathways, Annu Rev Immunol. 2000 (18): 143-164.
7. Sander Dinant, Reeta L. Vetelainen, Sandrine Florquin, et al. IL-10 Attenuates Hepatic I/R Injury and Promotes Hepatocyte Proliferation. Journal of Surgical Research. 2007, 141(2):176-182.
8. R.E. Engles, T.S. Huber, D.S. Zander, et al. Exogenous human recombinant interleukin-10 attenuates hindlimb ischemia-reperfusion injury. J Surg Res. 1997, 69(2): 425-428.
9. MJ. Eppinger, P.A. Ward, S.F. Boiling, et al. Regulatory effects of interleukin-10 on lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 1996,112(5): 1301-1305.
10. O. Le Moine, H. Louis, A. Demols, et al. Cold liver ischemia-reperfusion injury critically depends on liver T cells and is improved by donor pretreatment with interleukin 10 in mice. Hepatology. 2000,31 (6): 1266-1274.
11. R. Hayward, T.O. Nossuli, R. Scalia. et al. Cardioprotective effect of interleukin-10 in murine myocardial ischemia-reperfusion. Eur J Pharmacol. 1997,334 (2-3): 157-163.
12. Mingjian Fei, Xuefeng Wu, Qiang Xu. Astilbin inhibits contact hypersensitivity through negative cytokine regulation distinct from cyclosporin A. Journal of Allergy and Clinical Immunology, 2005,116(6): 1350-1356.
13. Alexander W.S, Starr R, Fenner J.E, et, al. SOCS1 is a critical inhibitor of interferon-gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell. 1999, 98: 597-608.
14. Marine J.C, McKay C, Wang D, et, al. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell. 1999, 8: 609-616.
15. Brysha M, Zhang JG, Bertolino P, et al. Suppressor of cytokine signaling-1 attenuates the duration of interferon y signal transduction in vitro and in vivo. J Biol Chem. 2001, 276:22086-22089.
16. Bi XL, Yang JY, Dong YX, et al. Resveratrol inhibits nitric oxide and TNF-alpha production by lipopolysaccharide-activated microglia. Int Immunopharmacol. 2005, 5(1):185-193.
17. Dalpke AH, Opper S, Zimmermann S, et. al. Suppressors of cytokine signaling(SOCS)-1 and SOCS-3 are induced by CpG-DNA and modulate cytokine responses in APCs. J Immunol, 2001,166 (12) :7082-7089.
18. Kinjyo I, Hanada T, Inagaki-Ohara K, et al. SOCS1/ JAB is a negative regulator of LPS-induced macrophage activation. Immunity, 2002,17: 583-591.
19. Guha M, Mack N. LPS induction of gene expression in human monocytes. Cell Signal, 2001,13(2): 85-94.
20. Raimann T, Buschen D, Hipskind RA, et al. Lipopolysaccharide induces activation of the Raf-1 in the induction of the IL-1 beta and the TNF-alpha genes. J Immunol, 1994,153 (12): 5740-5749.
21. Kinjyo I, Hanada T, Inagaki-Ohara K, et al. SOCS1/ JAB is a negative regulator of LPS-induced macrophage activation. Immunity, 2002,17: 583-591.
22. Nakagawa R, Naka T, Tsutsui H, et al. SOCS-1 participates in negative regulation of LPS responses. J Immunity, 2002,17: 677-687.
23. T. Kasama, R.M. Strieter, N.W. Lukacs, et al. Regulation of neutrophil-derived chemokine expression by IL-10. J Immunol. 1994,152 (7): 3559-3569.
24. M.R. de Waal, J. Abrams, B. Bennett, et al. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991,174 (5): 1209-1220.
25. D.F. Fiorentino, A. Zlotnik, T.R. Mosmann, et al. IL-10 inhibits cytokine production by activated macrophages. J Immunol. 1991,147(11): 3815-3822.
26. S. Song, H. Ling-Hu, K.A. Roebuck, et al. Interleukin-10 inhibits interferon-δ-induced intercellular adhesion molecule-1 gene transcription in human monocytes. Blood. 1997, 89 (12): 4461-4469.
27. A.J. Schottelius, M.W. Mayo, R.B. Sartor, et al. Interleukin-10 signaling blocks inhibitor of kB kinase activity and nuclear factor kB DNA binding. J Biol Chem. 1999, 274(45): 31868-31874.
28. J.K. Riley, K. Takeda, S. Akira, et aL Interleukin-10 receptor signaling through the JAK-STAT pathway Requirement for two distinct receptor-derived signals for anti-inflammatory action. J Biol Chem. 1999, 274(23): 16513-16521.
29. Bibo KE, Xiu-Da Shen, Sei-ichiro Tsuchihashi, et.al. Viral Interleukin-10 Gene Transfer Prevents Liver Ischemia-Reperfusion Injury: Toll-Like Receptor-4 and Heme Oxygenase-1 Signaling in Innate and Adaptive Immunity. Human Gene Therapy. 2007,18: 355-366.
1.Busuttil,R.W,Tanaka,K.The utility of marginal donors in liver transplantation.Liver Transplantation.2003,9(7):651-663.
2.Reddy S,Zilvetti M,Brockmann J,et al.Liver transplantation from non-heart-beating donors:current status and future prospects.Liver Transplantation.2004,10(10):1223-1232.
3.Franco-Gou R,Peralta C,Massip-Salcedo M,et al.Protection of reduced-size liver for transplantation.American Journal of Transplantation.2004,4(9):1408-1420.
4.Fondevila C,Busuttil RW,Kupiec-Weglinski JW.Hepatic ischemia/reperfusion injury-a fresh look.Exp Mol Pathol 2003;74:86.
5.Teoh NC,Farrell GC.Hepatic ischemia reperfusion injury:Pathogenic mechanisms and basis for hepatoprotection.J Gastroenterol Hepatol 2003;18:891.
6.Oyama J,Blais C Jr,Liu X,et al.Reduced myocardial ischemiareperfusion injury in toll-like receptor 4-deficient mice.Circulation 2004;109:784.
7.Wolfs TG,Buurman WA,van Schadewijk A,et al.In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells:IFN-gamma and TNF-alpha mediated up-regulation during inflammation.J Immunol 2002;168:1286.
8.Wu HS,Zhang JX,Wang L,et al.Toll-like receptor 4 involvement in hepatic ischemia/reperfusion injury in mice.Hepatobiliary Pancreat Dis Int 2004;3:250.9.Ke B,Shen XD,Gao F,et al.Interleukin 13 Gene Transfer in Liver Ischemia and Reperfusion Injury:Role of Stat6 and TLR4 Pathways in Cytoprotection.Hum Gene Ther 2004;15:691.
10.Yang BR,Mark MR,Gray A,et al.Toll-like receptor-2 mediates lipopolysac—charide-induced cellular signalling.Nature,1998,395(6699):284-288.
11. Kawai T, Adachi O , Ogawit T, et al. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity ,1999,11 (1): 115-122.
12. Takeuchi O , Takeda K, Hoshino K, et al . Cellular responses to bacterial cell wall components are mediated through MyD88-dependent signaling cascades. Int Immunol ,2000,12 (1) :113-117.
13. Thomas JA, Allen JL, Tsen M, et al. Impaired cytokine signaling in mice lacking the IL-1 receptor-associated kinase. J Immunol ,1999 ,163(2) :987-984.
14. Muzio M, Natoli G, Saccani S , et al. The human toll signaling pathway :diver- gence of nuclear factor kappaB and JNK/ SAPK activation upstream of tumor necro—sis factor receptor-associated factor 6 (TRAF6). J Exp Med, 1998,187 (12): 2097-2101.
15. Vogel SN, Johnson D , Perena PY, et al. Cutting edge : functional characteri—zation of the effect of the C3H/ HeJ defect in mice that lack an Lpsn gene : in vivo evidence for a dominant negative mutation. J Immnuol ,1999 ,162 (10) :5666-5670.
16. Qureshi ST ,Lariviere L ,Leveque G,et al. Endotoxin-tolerant mice have muta -tions in toll-like receptor 4 (Tlr4). J Exp Med ,1999 ,189 (4) :615-625.
17. Toshchakov V, Jones BW, Lentschat A, et al. TLR2 and TLR4 agonists stimulate unique repertoires of host resistance genes in murine macrophages-Interferon-beta-dependent signaling in TLR4-mediated responses . J Endotoxin Res 2003; 9: 169.
18. Rhee SH, Jones BW, Toshchakov V, et al. Toll-like receptors 2 and 4 activate STAT1 serine phosphorylation by distinct mechanisms in macrophages. J Biol Chem 2003; 278: 22506.
19. Akira S, Yamamoto M, Takeda K. Role of adapters in Toll-like receptor signal-ling. Biochem Soc Trans 2003; 31: 637.
20. Tamaru M, Nishioji K, Kobayashi Y, et al. Liver-infiltrating T lymphocytesare attracted selectively by IFN-inducible protein-10. Cytokine 2000; 12: 299.
21. Day YJ, Marshall MA, Huang L, et al. Protection from ischemic liver injury by activation of A2A adenosine receptors during reperfusion: Inhibition of chemokine induction. Am J Physiol Gastrointest Liver Physiol 2004; 286: G285.
22. Colletti LM, Green ME, Burdick MD, Strieter RM. The ratio of ELR_to ELR_CXC Chemokines affects the lung and liver injury following hepatic ischemia/ reperfusion in the rat. Hepatology 2000; 31: 435.
23.Asahina Y,Yoshioka N,Kano R,et.al.Full-lenth Cdna cloning of Toll-like receptor 4in dogs and cats.Vet Immunol Immunopathol,2003,96:159-167.
24.Matsumura T,Hayashi H,Takii T.TGF-beta down-regulates IL-1 alpha-induced TLR2expression in murine hepatocytes.J Leukoc Biol,2004,75:1056-1061.
25.Xiong J,Zhu ZH,Liu JS,Wang Y,Wu HS.The expression of toll-like receptor 2,4 of livers in mice with systemic inflammatory response syndrome.Hepatobiliary Pancreat Dis Int.2006;5(1):143-6.
26.Peng Y,Gong JP,Liu CA,et al.Expression of toll-like receptor 4 and MD-2 gene and protein in Kupffer cells after ischemia- reperfusion in rat liver graft.World J Gastroenterol,2004,10(19):2890-2893.
27.Tsung A,Hoffman RA,Izuishi K,et al.Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells.J Immunol,2005,175(11):7661-7668.
28.刘小伟,游宇,卢放根,等.脂多糖信号转导分子TLR4表达与小鼠肝损伤的关系.湖南医科大学学报,2003,28:217-220.
29.Allan Tsung,Rohit Sahai,Hiroyuki Tanaka,et.al.The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion.J Exp Med,2005,201(7):1135-1143.
30.Jun-ichi Oyama,Charles Blais,Jr,Xiaoli Liu,et.al.Reduced Myocardial Ischemia-Reperfusion Injury in Toll-Like Receptor 4-Deficient Mice.Circulation,2004(109):784-789.
31.Bibo KE,Xiu-Da Shen,1 Sei-ichiro Tsuchihashi,et.al.Viral Interleukin-10 Gene Transfer Prevents Liver Ischemia-Reperfusion Injury:Toll-Like Receptor-4 and Heme Oxygenase-1 Signaling in Innate and Adaptive Immunity.Human Gene Therapy,2007,18:355-366.
32.Sei-ichiro Tsuchihashi,Yuan Zhai,Qiao Bo,et.al.Heme Oxygenase-1 Mediated Cytoprotection Against Liver Ischemia and Reperfusion Injury:Inhibition of Type-1Interferon Signaling.Transplantation,2007,83(12):1628-1634.
33.Hui Yin a,Bao-jun Huang a,b,Heng Yang,et.al.Pretreatment with soluble ST2 reduces warm hepatic ischemia/reperfusion injury.Biochemical and Biophysical Research Communications 2006,351:940-946.
34. Greisman, S. E., E. J. Young, and F. A. J. Carozza. Mechanisms of endotoxin tolerance: specificity of the early and late phases of pyrogenic tolerance. J. Immunol. 1969,103: 1223-1236.
35. Tsung, A, R. Sahai, H. Tanaka, et, al. The nuclear factor HMGB1 mediateshepatic injury after murine liver ischemia-reperfusion. J. Exp. Med. 2005(201): 1135-1143.
36. Kunihiko Izuishi, Allan Tsung, Geetha Jeyabalan,et.al. Cutting Edge: High-Mobility Group Box 1 Preconditioning Protects against Liver Ischemia-Reperfusion Injury. The Journal of Immunology, 2006,176: 7154-7158.
37. Fontaine C, Rigamonti E, Nohara A,et.al. Liver X receptor activation potentiates the lipopolysaccharide response in human macrophages. Circ Res, 2007,101(1):40-9.
38. Wu J, Yu P, Hu Z, Zheng S. Statins can be the potential therapeutic agents for reducing infection evoked cholangiopathy after liver transplantation? Med Hypotheses. 2007 Aug 1; Epub ahead of print.
39. Miyaso H, Morimoto Y, Ozaki M,et.al. Protective effects of nafamostat mesilate on liver injury induced by lipopolysaccharide in rats: possible involvement of CD14 and TLR-4 downregulation on Kupffer cells. Dig Dis Sci. 2006, 51(11):2007-12.
40. Tsung A, McCoy SL, Klune JR,et.al. A novel inhibitory peptide of Toll-like receptor signaling limits lipopolysaccharide-induced production of inflammatory mediators and enhances survival in mice. Shock. 2007 Apr;27(4):364-9.
41. Mullarkey M, Rose JR, Bristol J, Kawata T, Kimura A, Kobayashi S, Przetak M, Chow J, Gusovsky F, Christ WJ, Rossignol DP. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther. 2003;304:1093-1102.
42. Akira Shimamoto, Albert J. Chong, Masaki Yada,et.al. Inhibition of Toll-like Receptor 4 With Eritoran Attenuates Myocardial Ischemia-Reperfusion Injury. Circulation 2006;114;I-270-I-274.
1、曹正中。土茯苓化学成分的研究.中草药,1993,24(5):234.
2、陈广耀,沈连生,江佩芬。土茯苓中二氢黄酮醇甙的研究。中国中药杂志,1996:21(6):355-357.
3、Eiattar TMA,Virji AS.Modulating efect of resveratol and quercetin on oral cancer cell growth and proliferation.Anti-Cancer Drugs,1999.10:187-193.
4、吴丽明,张敏。土茯苓中落新妇甙的利尿和镇痛作用。中药材,1995,18(12):627-630.
5、高思海,潘铁成。落新妇甙的提取及对心肌缺血再灌注损伤的保护作用研究。中华实用中西医杂志,2003,3(16):1693-1694.
6、Yan R,Xu Q.Astilbin selectively facilitates the apoptosis of interleukin-2-dependent phytohemagglutinin-activated jurkat cells.Pharmacol Res。2001,44:135-139.
7、高思海,李平,陈涛等。落新妇甙诱导混合细胞培养中活化的T细胞凋亡及其机制。中华器官移植杂志,2006,27(10):580-582.
8、高思海,陈涛,潘铁成.落新妇甙对同种反应性T细胞Bax,Bcl-2和easpase-3表达的影响.中华实用中西医杂志,2003,3(16):2110-2111.
9、高思海,李平,潘铁成.落新妇甙对同种反应性T细胞Fas,FasL和TNF-R1和TNF-R2基因表达的调控.中华实用中西医杂志,2004,4(17):217-218.
10、高思海,李平,陈涛等。落新妇甙对心脏移植效应性T细胞磷脂酰肌醇信号通路的影响。中华胸心血管外科杂志,2007,23(1):47-49.
11、Lafont V,Astoul E,Laurence A,et al.The T cell antigen receptor activates phosphatidylinositol 3-kinase-regulated serine kinases protein kinase B and ribosomal $6kinase 1.FEBS Lett,2000,486:38-42.
12、高思海,陈涛,潘铁成等。落新妇甙对心脏移植排斥反应中活化T细胞穿孔素和颗粒酶B表达的影响。中国医师杂志。2006,8(10):1336-1338.
13、陈涛,潘铁成,高思海等。落新妇甙对小鼠心脏移植排斥反应的抑制作用。山东医药,2006,46(33):7-8.
14、高思海,李平,陈涛等。落新妇甙对心脏移植排斥反应中细胞因子表达的影响。中华小儿外科杂志,2006,27(2):87-89.
15、徐广全,王斌,金相元,等.塞来昔布对大鼠心脏移植急性排斥反应的抑制作用[J].中华器官移植杂志,2006,27(2):105-106.
16、Z.L.Sun,T.Wada,et al.Role of Fas/Fasl in Kupffer cell-dependent deletion of alloantigen activated T cells following liver transplantation.Transplantation Proceedings.2001;33:279-282.
17、Xiao Yang Wang,Junhong Sun,et al.Effect of liver transplantation on islet allografts.Transplantation.2001;71(1):102-111.
18、J.Sun,X.Wang,et al.Increased Fas ligand expression and activated T-lymphocyte apoptosis in islet graft tolerance induced by liver transplantation. Transplantation Proceedings. 2001;33:227-228.
19 Wei Li, Lina LU, et al. IL-12 antagonism enhances apoptotic death of T cells within hepatic allografts from Flt3 ligand-treated donors and promotes graft acceptance. J. Immunol. 2001;166:5619-5628.
20 Wei Li, Lina LU, et al. Costimulation blockade promotes the apoptotic death of graft-infiltrating T cells and prolongs survival of hepatic allografts from Flt3 ligand-treated donors. Transplantation. 2001;72(8):1423-1432.
21 Xu Q, Wu F, Cap J, et al. Astilbin selectivelyinduces dysfunction of liver infiltrating cells—novel protection from liver damage. Eur J Pharm acol, 1999, 377: 93-100.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |